Prof. Dr. Meral Beksaç

Bildiriler

• DAHA ÖNCE YOĞUN TEDAVİ ALMIŞ RELAPS/REFRAKTERMULTİPL MİYELOM HASTALARINDA DARATUMUMABINETKİLİLİK VE GÜVENLİLİĞİ - BEKSAÇ MERAL,aydın yıldız,GÖKER HAKAN,TURGUT MEHMET,kalayoğlu beşışık sevgi,çağırgan seçkin,TUĞLULAR AYŞE TÜLİN,VURAL FİLİZ,YAĞCI ABDULLAH MÜNCİ,ALACACIOĞLU İNCİ,AYTAN PELİN,GÖKSOY HASAN SAMİ,gülbaş zafer,güneş ahmed kürşad,HACIOĞLU SİBEL,kartı sami,KAYNAR LEYLAGÜL,tekgündüz emre
• Analysis of Beta-catenin Mutations in Acute Myeloid Leukemia. - ALTINOK BUKET,ÖZKAN TÜLİN,KARADAĞ AYNUR,BEKSAÇ MERAL,SUNGUROĞLU ASUMAN
• Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide - BEKSAÇ MERAL,Delimpasi S.,,ROBAK P.,,Kim K.,,Wilkes J.,fulci giuilia,sule neal,kremer brandon,Dimopoulos MA
• External Valıdatıon Of Three Exıstıng Early Myeloma Relapse Scores (By Ebmt, Cıbmtr, And Gımema) In A Sıngle Center Shows Major Dıfferences - BEKSAÇ MERAL, CENGİZ SEVAL GÜLDANE, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, İLHAN OSMAN, GÜRMAN GÜNHAN
• Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study - BEKSAÇ MERAL,Iacobelli Simona,Luuk Gras Luuk,Koster Linda,Baaij Laurien,Hamad Nada,DSouza Anita,Estrada Noel,N Parameswaran,J Andrew,Saber Wael,Iida Minako,Okamoto Shinichiro,Takamatsu Hiroyuki,Mizuno Shohei,Kawamura Koji,Liam Christopher,Goh A Sim,Elhaddad Alaa M.,Bazarbach Ali,Alfar Rozan,Benakli Malek,Riva Eloisa,Galeano Sebastian,Mian Hira,Wang Feng Rong,Lv Meng,Neumann Daniel,Koh Mickey Boon Chai,Snowden John
• Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study - BEKSAÇ MERAL,FACON T.,,POUR L.,,HAJEK R.,,K. Liu,Minarik J.,,Moreau, P.,,Jarosinska Joanna Romejko,Vorobyev Vladimir I.,Ishida Tadao,Janowski Wojciech,Parma Gurdeep,Zamagni Elena,Goldschmidt Hartmut,Martin Thomas,Manier Salomon,Orlowski Robert Z.,Comerford Erin,Tian Claire,Msihid Jérôme,BEŞIŞIK SEVGİ
• Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial - BEKSAÇ MERAL,Dimopoulos MA,GAY F.,,Ludwig H.,,S. ZWEEGMAN,Petrucci MT,Corradini P.,,LİBERATİ AM,Cavo M.,,Andersen NF,CROOCKEWİT A.,
• Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM) - BEKSAÇ MERAL,Mian Hira,Dimopoulos MA,Schjesvold F.,,Shah N.,Gatt ME,C. Touzeau,Manier S.,Magen H.,Nadeem Omar
• Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM) - BEKSAÇ MERAL,Mian Hira,DİMOPOULOS MELETİOS A.,Schjesvold F.,,Shah N.,Gatt ME,C. Touzeau,Manier S.,Magen H.,Nadeem Omar,Li Shuli
• Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis - BEKSAÇ MERAL,Martin T.,Suzuki K.,,KNAUF W.,Tekle L.,Qiu Y.,
• Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) - BEKSAÇ MERAL,DİMOPOULOS MELETİOS A.,Boccadoro M.,,QUACH H.,,HULİN C.,,antonioli elisabetta,LELEU X.,,mangiacavalli silvia,Perrot A.,,Cavo M.,,BROİJL A.,,GAY F.,,MİNA R.,Nijhof N.,,Van de Donk N.W.C.J,Katodritou E.,,Schjesvold F.,,DELFORGE M.,DRİESSEN C.,,HAWKINS JOHN SPENCER,HAJEK R.,,Wang W.,,amorn anna sitthi,boer carla j.,CARSON R.,,Gries KS
• Otoimmün Hemolitik Anemi ve T-LGL Birlikteliği Nadir Bir Olgu - ERMİŞ GY, KÖKCÜ G., TOPRAK SELAMİ KOÇAK, BEKSAÇ MERAL, TOPÇUOĞLU PERVİN
• Hemofili A ve Multipl Miyelom Tanılı Hastada Otolog Periferik Kök Hücre Mobilizasyonu: Olgu Sunumu - ÇALIŞ U., ERMİŞ GY, YILDIRIM Y.,, CENGİZ SEVAL GÜLDANE, TOPRAK SELAMİ KOÇAK, BEKSAÇ MERAL
• Kök hücre toplamada Plerixafor' un yeri: Kemoterapisiz de olur mu? - KARAKAYA B.,, CENGİZ SEVAL GÜLDANE, CİVRİZ BOZDAĞ SİNEM, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, GÜRMAN GÜNHAN, İLHAN OSMAN, BEKSAÇ MERAL, TOPRAK SELAMİ KOÇAK
• Myelofibroziste allojenik hematopoetik kök hücre nakli sonuçları: tek merkez deneyimi - SÖNMEZ MEHMET, CENGİZ SEVAL GÜLDANE, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, DEMİRER TANER, GÜRMAN GÜNHAN, İLHAN OSMAN, BEKSAÇ MERAL, ÖZCAN MUHİT
• Siklofosfamid ile Mobilizasyonunun Multipl Miyelom Hastalarında Nakil Sonuçlarına Etkileri - GÜVEN M., AKKUŞ ERMAN, CENGİZ SEVAL GÜLDANE, KÖKCÜ G., CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM, BEKSAÇ MERAL, TOPÇUOĞLU PERVİN
• MULTİPL MİYELOMDA KILLER IMMUNOGLOBULIN-LIKERESEPTÖRLERİ (KIR) VE LİGANDLARI İLE HLA- GRUP C1 VEC2’NİN SIKLIĞI - BEKSAÇ MERAL,Yurdakul Pınar,akın yalım,Aydın Gözde,Bunsuz Şengün Merve,ŞAHİN UĞUR,MERTER MUSTAFA,DALVA KLARA
• KIR2DS4’ÜN MİYELOM PLAZMA HÜCRELERİNE KARŞIOTOLOG VEYA KORDON KANI DOĞAL ÖLDÜRÜCÜ HÜCREARACILIKLI TOKSİSİTEDE ROLÜ - YURDAKUL MESUTOĞLU PINAR,Akın Hasan Yalım,Bunsuz Şengün Merve,Turasan Eylül,MERTER MUSTAFA,Öztürk Cemaleddin,DALVA KLARA,BEKSAÇ MERAL
• İndüksiyon Mu Hazırlama Rejimi Mi Daha Önemli? İndüksiyon Sonrası Kalıntı Hastalığın Saptanamaması Bir Prognostik Gösterge Olabilir - CENGİZ SEVAL GÜLDANE,BAKANAY ÖZTÜRK ŞULE MİNE,MERTER MUSTAFA,ŞAHİN UĞUR,USLU ATİLLA,NARLI ÖZDEMİR ZEHRA,öztürk cemaleddin,DALVA KLARA,İLHAN OSMAN,BEKSAÇ MERAL
• Multipl miyelomda Killer Immunoglobulin like Reseptörleri (KIR) ve ligandları ile HLA- Grup C1 ve C2'nin sıklığı - BEKSAÇ MERAL, YURDAKUL PINAR, AKIN HASAN YALIM, AYDIN GÖZDE, ŞENGÜN MERVE BUNSUZ, ŞAHİN UĞUR, MERTER MUSTAFA, DALVA KLARA
• Decreased Multiple Myeloma Viability of Malignant Plasma Cells by Inhibition of Werner Helicase - AKÇORA YILDIZ DİLARA,ÖZKAN TÜLİN,ÖZEN MEHMET,Gündüz Mehmet,BEKSAÇ MERAL,SUNGUROĞLU ASUMAN
• OTOLOG PERİFERİK KÖK HÜCRE NAKLİNDE KÖK HÜCRESAKLANMA SÜRESİ ENGRAFMAN SÜRESİNİ ETKİLER Mİ? - MERTER MUSTAFA,Güleç Buğse,Özcan Gökçe,Zehra Özdemir Zehra,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,DEMİRER TANER,ÖZCAN MUHİT,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,GÜRMAN GÜNHAN,TOPRAK SELAMİ KOÇAK
• ALLOJENEİK HEMATOPOETİK KÖK HÜCRE NAKLİ SONRASI AKUT MYELOİD LÖSEMİ NÜKSÜNÜN YÖNETİMİ VE PROGNOZU - ŞAHİN UĞUR,GÜNDÜZ MEHMET,MERTER MUSTAFA,NARLI ÖZDEMİR ZEHRA,ÖZEN MEHMET,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN,TOPÇUOĞLU PERVİN
• YENİ TANI KLL HASTALARINDA TANI SIRASINDAKİ CD49DEKSPRESYONUNUN HASTALIĞA OZGU BAŞKA PARAMETRELERLEİLİŞKİSİ - TOPRAK SELAMİ KOÇAK,güven mustafa,CENGİZ SEVAL GÜLDANE,DALVA KLARA,İpek Şenay,Okul Nihal,Aral Dilara,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Evaluating response to treatment in patients with EMD - BEKSAÇ MERAL
• Post-authorization safety of lenalidomide+dexamethasone in patients with multiple myeloma in Turkey - BEKSAÇ MERAL
• Current status & updates in the management of AL amyloidosis - BEKSAÇ MERAL
• The potential of studying circulating plasma cells in multiple myeloma - BEKSAÇ MERAL
• Updates of ongoing EMN studies - BEKSAÇ MERAL
• Quadruplet therapy with and without autoHSCT in NDMM - BEKSAÇ MERAL
• Extramedullary Dısease - BEKSAÇ MERAL
• Plasma Cell Disorders subcommittee Project Presentations - BEKSAÇ MERAL
• Multipl Miyelom ve yeni nesil tedavi seçenekleri - BEKSAÇ MERAL
• Extramedullary myeloma - BEKSAÇ MERAL
• Special Lectures on Extramedullary Disease - BEKSAÇ MERAL
• Selecting frontline treatments strategies & monitoring patients with multiple myeloma - BEKSAÇ MERAL
• Preventing and managing post-transplant complications in multiple myeloma - BEKSAÇ MERAL
• Risk assessment & transplant decisions in multiple myeloma - BEKSAÇ MERAL
• The value of MRD as a prognostic tool in myeloma - BEKSAÇ MERAL
• An insight into familial myeloma - BEKSAÇ MERAL
• Multiple myeloma - BEKSAÇ MERAL
• Plasma cell disorders subcommittee projects presentation - BEKSAÇ MERAL
• A Focus on Multiple Myeloma - BEKSAÇ MERAL
• Contemporary Management of AL Amyloidosis - BEKSAÇ MERAL
• MRD to drive therapy - BEKSAÇ MERAL
• Efficacy and outcome of modern standard treatment vs. ASCT in newly diagnosed multiple myeloma patients - BEKSAÇ MERAL
• EBMT scoring system for early relapse after auto-HCT in MM Patients - BEKSAÇ MERAL
• Pomalidomide (POM), bortezomib (BORT), and dexamethasone (DEX) after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): a safety subanalysis of the phase 3 OPTIMISMM trial - Weisel K.,, Dimopoulos MA, Oriol A.,, BEKSAÇ MERAL, Schjesvold F.,, LİBERATİ A.,, LİNDSAY J.,, White D., San-Miguel J.,, Moreau, P.,, Anderson LD, LAROCCA A.,, ROBAK P.,, Vogel P., Jiang RY, GROTE T.,, PELUSO T.,, Richardson P.G.
• Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome - KIRCALİ EKİN, CENGİZ SEVAL GÜLDANE, CİVRİZ BOZDAĞ SİNEM, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, GÜRMAN GÜNHAN, BEKSAÇ MERAL, İLHAN OSMAN, TOPRAK SELAMİ KOÇAK
• Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience - İLHAN OSMAN, YAVUZ G.,, CENGİZ SEVAL GÜLDANE, CİVRİZ BOZDAĞ SİNEM, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, GÜRMAN GÜNHAN, BEKSAÇ MERAL
• Graft Versus Host Hastalığı Profilaksisinde ATG Ve Post CY Kullanımının Nakil Sonuçlarına Etkisi: Tek Merkez Deneyimi - KARAKAYA B.,, ŞAHİN Yİ, Mammadlı H., ERMİŞ GY, CENGİZ SEVAL GÜLDANE, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, İLHAN OSMAN, GÜRMAN GÜNHAN, YÜKSEL MELTEM
• İkinci Allojeneik Kök Hücre Nakli: Gerçek Yaşam Verisi - KIRCALİ EKİN, CENGİZ SEVAL GÜLDANE, ÖZTÜRK C.,, YILMAZ H.,, ERMİŞ GY, KARAKAYA B.,, DALVA KLARA, CİVRİZ BOZDAĞ SİNEM, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, GÜRMAN GÜNHAN, İLHAN OSMAN, BEKSAÇ MERAL, TOPRAK SELAMİ KOÇAK
• Amniyon Sıvısının, VPA İle Ekspande Hematopoietik Kök Hücre Nakli Sonrası Engrafmana Etkisinin İn Vivo Araştırılması - ÖNCÜL EMİNE BEGÜM GENCER, TURASAN EYLÜL, YOUSEFZADEH MAHSA, AKIN Hasan Yalım, YURDAKUL MESUTOĞLU PINAR, DALVA KLARA, BEKSAÇ MERAL
• OKHN Sonrası İlk 12 Ayda Nüksü Belirlemede Gımema Ve CIBMTR Skorlama Yaklaşımlarının Bağımsız Hasta Grubunda Validasyonu - BEKSAÇ MERAL, CENGİZ SEVAL GÜLDANE, KOYUN DERYA, YILMAZ H.,, KARAKAYA B.,, AKBULUT H., AYDOĞAN M., ÖZCAN MUHİT, GÜRMAN GÜNHAN, İLHAN OSMAN
• Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19) - BEKSAÇ MERAL, TUĞLULAR AYŞE TÜLİN, GAY F.,, MİNA R., Katodritou E.,, ÜNAL A.,, Cavo M.,, Ozsan H.,, Van De Velde H.,, BEVERLOO B., Vermeulen J.,, van Duin M., CENGİZ SEVAL GÜLDANE, ONGUN SEVİNDİK TUĞBA, Merante S., Manousou K., Sonneveld P.,, Terpos E.,
• Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study - Dimopoulos MA, Terpos E.,, Boccadoro M.,, Delimpasi S.,, BEKSAÇ MERAL, Katodritou E.,, Moreau, P.,, Baldini L.,, Symeonidis A.,, Bila J.,, Oriol A.,, Mateos MV, Einsele H.,, Orfanidis L.,, Kampfenkel T.,, K. Liu, KOSH M., Tran N.,, Carson R., Sonneveld P.,
• Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021 - Hayden P.J.,, Eikema DJ, KOSTER L.,, Snowden JA, Caillot D., Gorkom GV, Griskevicius L., Arcese W., Crawley C., Musso M., Bulabois CE, Martin AM, Netelenbos T., McDonald A., Maertens J., Parma M., Illes P., Isaksson C., Sossa C., Drozd-Sokolowska J.,, RAJ K., BEKSAÇ MERAL, Schönland S.,, McLornan DP, Yakoub-Agha I.,
• Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies - Richardson P.G., Perrot A.,, San-Miguel J.,, BEKSAÇ MERAL, Spicka I.,, LELEU X.,, Schjesvold F.,, Moreau, P.,, Dimopoulos MA, HUANG H.,, Minarik J.,, Cavo M.,, Prince M.,, MACE S.,, Malinge D.,, Dubin F.,, MORİSSE M., Anderson K.C
• 64th ASH Annual Meeting & Exposition - YILMAZ H.,, CENGİZ SEVAL GÜLDANE, KARAKAYA B.,, YAVUZ G.,, AYDOĞAN M., CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, İLHAN OSMAN, BEKSAÇ MERAL
• MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma - ZAMAGNİ E.,, Boccadoro M.,, Spencer A.,, DELFORGE M., Reece D., Einsele H.,, Terpos E.,, Schjesvold F.,, Bila J.,, DRİESSEN C.,, BEKSAÇ MERAL, Cook G.,, Rodriguez-Otero P.,, Pei HL, SHİN HJ, Sakabedoyan C., Jasielec J., Amin H.,, KOBOS R.,, Sonneveld P.,, Van de Donk N.,
• The efficacy and safety of second allogeneic hematopoietic stem cell transplantation - TOPRAK SELAMİ KOÇAK, KIRCALİ EKİN, CENGİZ SEVAL GÜLDANE, CİVRİZ BOZDAĞ SİNEM, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, GÜRMAN GÜNHAN, BEKSAÇ MERAL, İLHAN OSMAN
• Ibrutınıb As A Promısıng Treatment For Waldenström Macroglobulınemıa - İLHAN OSMAN, CENGİZ SEVAL GÜLDANE, AVCU F., Ferhanoglu B., ÖZCAN MUHİT, ÇETİN G., KURTOĞLU E., YILMAZ H.,, ATALAY FİGEN, GÜLTÜRK E., Nalcaci M., BEKSAÇ MERAL
• Carfılzomıb, Lenalıdomıde, Dexamethasone Followed By A Second Auto-Hct Is An Effectıve Strategy In Fırst Relapse Multıple Myeloma: A Study Of The Chronıc Malıgnancıes Workıng Party Of EBMT - Tilmont R., Yakoub-Agha I.,, Eikema DJ, ZİNGER N.,, Haenel M., Schaap N., Herrera Arroyo C., Schuermans C., Bethge W., ENGELHARDT M.,, Kuball J., Michieli M., Schub N., Wilson KMO, Bourhis JH, Mateos MV, Robin N., Jost E., KRÖGER N.,, Moraleda JM, Sica S., Hayden P.J.,, BEKSAÇ MERAL, Schönland S.,, MANİER S.,
• Daratumumab Plus Bortezomıb And Dexamethasone Versus Bortezomıb And Dexamethasone Alone In Patıents Wıth Prevıously Treated Multıple Myeloma: Overall Survıval Results From The Phase 3 Castor Trıal - Sonneveld P.,, Chanan-Khan A., Weisel K.,, Nooka A.,, Masszi T.,, BEKSAÇ MERAL, Spicka I.,, Hungria V.,, MUNDER M.,, Mateos MV, MARK TM, LEVİN MD, AHMADİ T.,, Qin X.,, Mayo WG, Gai X., Carey J., Carson R., Spencer A.,
• Response And Vaccınatıon Status Or Lack Of Immunoparesıs Are Assocıated Wıth Better Outcome Followıng Covıd-19 Infectıon Among Patıents Dıagnosed Wıth Multıple Myeloma: A Sıngle Center Experıence On 110 Patıents - CENGİZ SEVAL GÜLDANE, KIRCALİ EKİN, KOYUN DERYA, KARAKAYA B.,, YILMAZ H.,, AKBULUT H., TOPRAK SELAMİ KOÇAK, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, İLHAN OSMAN, BEKSAÇ MERAL
• Pomalıdomıde, Bortezomıb, And Dexamethasone In Lenalıdomıde–Pretreated Multıple Myeloma: A Subanalysıs Of Optımısmm By Fraılty - Oriol A.,, Dimopoulos MA, Schjesvold F.,, BEKSAÇ MERAL, YAĞCI M.,, LAROCCA A.,, Guo M.J.,, MU Y., Hong K., Dhanasiri S., Richardson P.G., Weisel K.,
• Ex Vivo Epigenetic Modification with Valproic Acid (VPA) Plus Nicotinamide (NAM) Results in Expansion of Umbilical Cord Blood Hematopoietic Progenitors Leading to Faster Engraftment and Chimerism in In Vivo Mouse Xenograft Model - ÖNCÜL EMİNE BEGÜM GENCER, TURASAN EYLÜL, AKIN Hasan Yalım, YURDAKUL MESUTOĞLU PINAR, SEVAL MURAT, ÇAĞAN M.,, KOÇ FAİK ACAR, BEKSAÇ MEHMET SİNAN, BEKSAÇ MERAL, DALVA KLARA
• Phase 3 Study of Belantamab Mafodotin with Pomalidomide (Pom) + Dexamethasone (Dex) vs Bortezomib + Pom/Dex in Relapsed/Refractory Myeloma - Suzanne T., Kalpana B., BEKSAÇ MERAL, Bikramjit C., Randy D., Delimpasi S.,, Meletis D., Moore A., Hang Q., Vorobyev V., Wilkes J., Wu F.
• Daratumumab(DARA)+Bortezomib/Cyclophosphamide/Dexamethasone (D-VCd) in Newly Diagnosed AL Amyloidosis: 18-month Landmark Analysis of ANDROMEDA - Suzuki K.,, Comenzo RL., Palladini G.,, Kastritis E.,, Minnema MC, Wechalekar AD, Jaccard A.,, Angela D., Lee HC, Sanchorawala V.,, Gibbs S.,, Mollee P.,, Venner C.,, Schönland S.,, Kihyunk K., Seattlecca E., BEKSAÇ MERAL, Bumma N.,, Merlini G.,
• Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone in Patients With Previously Treated Multiple Myeloma: Overall Survival Results From the Phase 3 CASTOR Trial - Sonneveld P.,, Chanan-Khan A., Weisel K.,, Nooka A.,, Masszi T.,, BEKSAÇ MERAL, Spicka I.,, Hungria V.,, MUNDER M.,, Mateos MV, MARK TM, LEVİN MD, AHMADİ T.,, Qin X.,, Mayo WG, Gai X., Carey J., Carson R., Spencer A.,
• An Early Post-Transplant Relapse Predıctıon Score In Multıple Myeloma Patıents: A Large Cohort Study From Chronıc Malıgnancıes Workıng Party Of EBMT - BEKSAÇ MERAL
• Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty - Rocafiguera AO, Dimopoulos MA, Schjesvold F.,, BEKSAÇ MERAL, YAĞCI M.,, LAROCCA A.,, Guo M.J.,, MU Y., Hong K., Dhanasiri S., Richardson P.G., Weisel K.,
• EX VIVO EXPANSION OF HUMAN UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELLS (HSCS) WITH VALPROIC ACID (VPA) OR NEUROTROPHIC FACTOR (NTF) - Akin H,YURDAKUL PINAR,Aydin G,DALVA KLARA,BEKSAÇ MERAL
• Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience - TOPÇUOĞLU PERVİN,SEVAL GÜLDANE CENGİZ,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,DALVA KLARA,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• KIR 2DS4 May Influence Autologous and Cord Blood(CB) Natural Killer (NK)Cell Mediated in Vitro Cytotoxicity Against Freshly Isolated Human Bone Marrow Myeloma Plasma Cells and Cell Lines - YURDAKUL MESUTOĞLU PINAR,AKIN HY,BUNSUZ M,,TURASAN E,,MERTER MUSTAFA,ÖZTÜRK CEMALETTİN,DALVA KLARA,BEKSAÇ MERAL
• The Outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4(+) T-cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect - YÜKSEL MELTEM,NARLI ÖZDEMİR ZEHRA,ŞAHİN UĞUR,ÇAĞDAŞ AYVAZ DENİZ NAZİRE,TURKUM ATIKCAN DENİZ,SERTESEN ELİF,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,GÜRMAN GÜNHAN,İKİNCİOĞULLARI KAMİLE AYDAN
• Carfilzomib ve Pomalidomid Etkinliğinin Retrospektif Değerlendirilmesi: Ankara Üniversitesi Deneyimi - AKKUŞ ERMAN,MERTER MUSTAFA,ŞAHİN UĞUR,NARLI ÖZDEMİR ZEHRA,ATACA ATİLLA PINAR,TOPÇUOĞLU PERVİN,BEKSAÇ MERAL
• Ankara Üniversitesi Tıp Fakültesi Multiple Myelom Elotuzumab ve İmmünmodulatuar İlaç Tedavi Deneyimi - KARAMAN ZEHRA,ŞAHİN UĞUR,MERTER MUSTAFA,GÜNDÜZ MEHMET,ÖZEN MEHMET,BEKSAÇ MERAL
• İmmun Trombositopenide (İTP) Yenilikler Işığında Klinik Retrospektif Değerlendirme: Tek Merkez Deneyimi - AKKUŞ ERMAN, KUŞTAŞ ALİ AYTUĞ, PEKCAN GÜLTEKİN, MERTER MUSTAFA, ŞAHİN UĞUR, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, İLHAN OSMAN, AKAN HAMDİ, BEKSAÇ MERAL, GÜRMAN GÜNHAN, YÜKSEL MELTEM
• Clonal Plasma Cell Detection by High Sensitive Flow Cytometry in Aphaeresis Product is Poor Prognostıc and not Increased by Use of Plerixafor Alone - CENGİZ SEVAL GÜLDANE,USLU A,,DALVA KLARA,BAKANAY SM,MERTER MUSTAFA,ŞAHİN UĞUR,İLHAN OSMAN,BEKSAÇ MERAL
• Evaluating peritransplant albumin decline as a predictor of acute graft versus host disease - MERTER MUSTAFA,YÜKSEL MELTEM,demir en,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
• Large unstained cell percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation - MERTER MUSTAFA,Köken K,YÜKSEL MELTEM,Demir EN,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL
• Therapeutic Thrombocytapheresis: Higher Platelet Counts Should Matter - NARLI ÖZDEMİR ZEHRA,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ÖZCAN MUHİT,ARSLAN ÖNDER,DEMİRER TANER,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Heparin Enhances CD34 Content of Stem Cells Collected Following G-CSF +/- Chemotherapy - MERTER MUSTAFA, ŞAHİN UĞUR, YILDIRIM YASİN, İLHAN OSMAN, BEKSAÇ MERAL
• A prospective analysis on the frequency and predictive value of minimal residual disease assessment by flow cytometry and PET-CT imaging among myeloma patients on/off maintenance - BEKSAÇ MERAL,CENGİZ SEVAL GÜLDANE,ŞAHİN UĞUR,MERTER MUSTAFA,İPEK ŞENAY,ÖZKAN ELGİN,DALVA KLARA
• A Preliminary Analysis of Inherited Immune Checkpoint Control in Multiple Myeloma: Relative Frequency of Inhibitory or Activating Type Killer Immunoglobulin like Receptors and Their Cognate Ligands HLA-C1 and -C2 - BEKSAÇ MERAL, YURDAKUL PINAR, AKIN H. YALIM, AYDIN GOZDE, BUNSUZ ŞENGÜN MERVE, ŞAHİN UĞUR, MERTER MUSTAFA, DALVA KLARA
• Residual Clonal Plasma Cells Detected by Flow Cytometry at 10-4 Level within Autologous Stem Cell Grafts is Associated with Significantly Less Overall Survival - CENGİZ SEVAL GÜLDANE,DALVA KLARA,BAKANAY SM,,MERTER MUSTAFA,ŞAHİN UĞUR,USLU ATİLLA,ÖZTÜRK CEMALETTİN,İLHAN OSMAN,BEKSAÇ MERAL
• Multipl Miyelom Olgularında Otolog Kök Hücre Naklinde Yüksek Doz Melfelana Bortezomib Eklenmesinin Tek Merkez Sonuçları - CENGİZ SEVAL GÜLDANE,KOYUN DERYA,KIRCALİ EKİN,ŞAHİN UĞUR,TOPRAK SELAMİ KOÇAK,ÖZCAN MUHİT,BEKSAÇ MERAL
• Plerixafor, Periferik Kök Hücre Ürününde Akım Sitometri İle Saptanabilen Klonal Plazma Hücre Kontaminasyonunu Etkiler Mi? - CENGİZ SEVAL GÜLDANE,USLU ATİLLA,DALVA KLARA,BAKANAY ÖZTÜRK ŞULE MİNE,MERTER MUSTAFA,ŞAHİN UĞUR,İLHAN OSMAN,BEKSAÇ MERAL
• The Effect Of Predıcted Indırectly Recognızable Hla Epıtopes Presented By Hla-Class Iı Molecules On 1 Antıgen/Alelle Mısmatched Unrelated Hsct: A Sıngle Center Experıence - DALVA KLARA,CENGİZ SEVAL GÜLDANE,OZ dilek,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,Alnıaçık EZGİ,ALTAN HİLAL,ALNIAÇIK RIDVAN,SERTEL SUAT,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Can Nelarabıne Rescue The Graft After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon In T-All ? - YÜKSEL MELTEM,CENGİZ SEVAL GÜLDANE,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,İLHAN OSMAN,GÜRMAN GÜNHAN
• Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation - CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL
• Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset - AKIN HY, CENGİZ SEVAL GÜLDANE, ATİLLA PA, YURDAKUL MESUTOĞLU PINAR, TANER OTLU, ALNIAÇIK R.,, DALVA KLARA, GÜRMAN GÜNHAN, BEKSAÇ MERAL
• Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation - CENGİZ SEVAL GÜLDANE, DALVA KLARA, ÖZ MEMNUNE DİLEK, ÖZTÜRK SMB, SOYDAN E.,, GÜRMAN GÜNHAN, İLHAN OSMAN, BEKSAÇ MERAL
• Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience - DEMİRER TANER,CENGİZ SEVAL GÜLDANE,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,İLHAN OSMAN,GÜRMAN GÜNHAN,BEKSAÇ MERAL,ÖZCAN MUHİT
• A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm - ÖZCAN MUHİT,KOYUN DERYA,CENGİZ SEVAL GÜLDANE,USLU ATİLLA,KIRCALİ EKİN,ÖZTÜRK CEMALETTİN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,İLHAN OSMAN,BEKSAÇ MERAL
• Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients? - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation - DEMİRER TANER,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis - CENGİZ SEVAL GÜLDANE,ÖZTÜRK N,,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
• KIR Genotype and KIR Ligand Phenotypes That Improve the in Vitro Cord Blood or Autologous NK Cell Mediated Cytotoxicity Against Myeloma Marrow Plasma Cells - AKIN HY,TURASAN E,,KIRCALİ E,,AKKUŞ ERMAN,CENGİZ SEVAL GÜLDANE,YURDAKUL MESUTOĞLU PINAR,DALVA KLARA,BEKSAÇ MERAL
• Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow - CENGİZ SEVAL GÜLDANE,USLU ATİLLA,KIRCALİ E,,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,DALVA KLARA,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• A retrospective single center experience with the generic of lenalidomide Rivelime (R) compared with original patented drug Revlimid (R) - BEKSAÇ MERAL,CENGİZ SEVAL GÜLDANE,KOYUN DERYA,TOPÇUOĞLU PERVİN,YÜKSEL MELTEM,GÜRMAN GÜNHAN,İLHAN OSMAN
• Is post-transplant albumin a predictor of early transplant complications? - TOPÇUOĞLU PERVİN,CENGİZ SEVAL GÜLDANE,AKKUŞ ERMAN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Ruxolitinib in steroid refractory GVHD treatment: single center experience - CENGİZ SEVAL GÜLDANE,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,BEKSAÇ MERAL
• Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen - İLHAN OSMAN, CENGİZ SEVAL GÜLDANE, USLU ATİLLA, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, AKAN HAMDİ, BEKSAÇ MERAL, GÜRMAN GÜNHAN
• Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma - CENGİZ SEVAL GÜLDANE,SERTESEN ELİF,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
• Results Of A Sıngle Center Experıence: An Attempt To Augment Condıtıonıng Regımen In Fırst Autologous Stem Cell Transplantatıon - CENGİZ SEVAL GÜLDANE,KOYUN D,,KİRCALİ E,,TOPRAK SELAMİ KOÇAK,ÖZCAN MUHİT,BEKSAÇ MERAL
• Is mobilization with chemotherapy effect response in the multiple myeloma? - CENGİZ SEVAL GÜLDANE,USLU A,,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPÇUOĞLU PERVİN
• Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,USLU A,,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Treatment Of Thrombocytopenıa After Allogeneıc Stem Cell Transplantatıonwıth Eltrombopag - KIRCALİ EKİN, CENGİZ SEVAL GÜLDANE, KOYUN DERYA, ÖZTÜRK CEMALETTİN, USLU ATİLLA, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, AKAN HAMDİ, İLHAN OSMAN, GÜRMAN GÜNHAN, BEKSAÇ MERAL, YÜKSEL MELTEM
• Flamsa-Based Hıgh-Dose Sequentıal Condıtıonıng Regımen Followed By Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allo-Hsct): Is It Effectıveın Patıents Wıth Prımary Refractory Or Relapsed Acute Leukemıa? - CENGİZ SEVAL GÜLDANE,EKİN KIRCALİ,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPÇUOĞLU PERVİN
• The Influence Of Antı-Thymocyte Globulın (Atg) On The Outcomes Of Patıents Wıth Aml W/Wo Measurable Resıdual Dısease (Mrd) At The Tıme Of Unrelated Donor Transplantatıon - CENGİZ SEVAL GÜLDANE, KIRCALİ EKİN, BALTACI MEHMET AKİF, CİVRİZ BOZDAĞ SİNEM, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, DALVA KLARA, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, GÜRMAN GÜNHAN, İLHAN OSMAN, AKAN HAMDİ, BEKSAÇ MERAL, TOPRAK SELAMİ KOÇAK
• Role Of Chımerısm And Flow-Cytometrıc Monıtorıng Of Measurable Resıdualdısease (Mrd) After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allohsct) In Predıctıng Relapse In Acute Myeloıd Leukemıa (AML) - CENGİZ SEVAL GÜLDANE, ULAŞ ELİZ BAHAR, TOPRAK SELAMİ KOÇAK, CİVRİZ BOZDAĞ SİNEM, YÜKSEL MELTEM, TOPÇUOĞLU PERVİN, DALVA KLARA, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, İLHAN OSMAN, AKAN HAMDİ, BEKSAÇ MERAL, GÜRMAN GÜNHAN
• Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data - CENGİZ SEVAL GÜLDANE,USLU ATİLLA,KİRCALİ EKİN,CİVRİZ BOZDAĞ SİNEM,DALVA KLARA,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,KUZU IŞINSU,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia? - KIRCALİ EKİN,CENGİZ SEVAL GÜLDANE,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPÇUOĞLU PERVİN
• Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis - CENGİZ SEVAL GÜLDANE,ÖZTÜRK NERGİS,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
• Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs - CENGİZ SEVAL GÜLDANE,KUZU IŞINSU,YÜKSEL SEHER,KAYGUSUZ GÜLŞAH,DALVA KLARA,ÖZCAN MUHİT,BEKSAÇ MERAL
• Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic - BEKSAÇ MERAL, TUĞLULAR T.,, ÜNAL A.,, Cavo M.,, Gay Francesca, KATODRITOU EIRINI, ÖZSAN GÜNER HAYRİ, CENGİZ SEVAL GÜLDANE, SEVİNDİK ÖMÜR GÖKMEN, Merante Serena, Manousou Kyriaki, Sonneveld P.,, Terpos E.,
• KILLER IMMUNOGLOBULIN LIKE HAPLOTYPE BB IS OBSERVED MORE FREQUENTLY AMONG MYELOMA CASES COMPARED TO HEALTHY CONTROLS - AKIN Hasan Yalım, ATACA ATİLLA PINAR, YURDAKUL MESUTOĞLU PINAR, CENGİZ SEVAL GÜLDANE, OTLU TANER, ALNIAÇIK R.,, DALVA KLARA, GÜRMAN GÜNHAN, BEKSAÇ MERAL
• CAN ELTROMBOPAG TREAT THE THROMBCYTOPENIA AFTER STEM CELL TRANSPLANTATION - YÜKSEL MELTEM,KIRCALI EKİN,CENGİZ SEVAL GÜLDANE,KOYUN DERYA,USLU ATİLLA,ÖZTÜRK CEMALEDDİN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,BEKSAÇ MERAL,ÖZCAN MUHİT,İLHAN OSMAN,ARSLAN ÖNDER,AKAN HAMDİ,DEMİRER TANER,GÜRMAN GÜNHAN
• PRE-TRANSPLANT HEMOGLOBIN AND SERUM CREATININE LEVELS CORRELATE WITH PROGRESSION FREE SURVIVAL IN MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION - CENGİZ SEVAL GÜLDANE,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
• LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER - CENGİZ SEVAL GÜLDANE,USLU ATİLLA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,İLHAN OSMAN
• CAN AUTOLOGOUS STEM CELL TRANSPLANTATIONABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH? - CENGİZ SEVAL GÜLDANE,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
• POSTTRANSPLANT LENFOSİTOZ ÖNEMLİ BİR PARAMETRE MİDİR? - CENGİZ SEVAL GÜLDANE,USLU ATİLLA,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,CİVRİZ BOZDAĞ SİNEM
• AKUT MİYELOİD LÖSEMİDE NAKİL ÖNCESİ MİNİMAL KALINTI HASTALIK DİĞER RİSK FAKTÖRLERİNDEN DAHA ÖNEMLİ MİDİR? - NARLI ÖZDEMİR ZEHRA,ŞAHİN UĞUR,BALTACI MEHMET AKİF,USLU ATİLLA,ÖZTÜRK C,,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,BEKSAÇ MERAL,İLHAN OSMAN,GÜRMAN GÜNHAN
• Yurt İçi Ve Yurt Dışı Gönüllü Akaraba Dışı Vericilerde HLA Özdeşlik Durumu : 10/10 >9/10 Mu Yoksa En Büyük HLADPB1 Mi? - YÜKSEL MELTEM, CENGİZ SEVAL GÜLDANE, DALVA KLARA, CEYLAN G.,, AKAL F.,, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, TOPÇUOĞLU PERVİN, GÜRMAN GÜNHAN, BEKSAÇ MERAL
• ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN ALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİL SONUÇLARINA ETKİLERİ - KALACI ENDER,ŞAHİN EROĞLU DİDEM,CENGİZ SEVAL GÜLDANE,NARLI ÖZDEMİR ZEHRA,BEKSAÇ MERAL,ÖZCAN MUHİT,ARSLAN ÖNDER,İLHAN OSMAN,TOPÇUOĞLU PERVİN,GÜRMAN GÜNHAN,TOPRAK SELAMİ KOÇAK,DEMİRER TANER,YÜKSEL MELTEM,CİVRİZ BOZDAĞ SİNEM
• Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Akut Myeloid Lösemi Nüksünün Yönetimi ve Prognozu - ŞAHİN UĞUR,GÜNDÜZ MEHMET,MERTER MUSTAFA,NARLI ÖZDEMİR ZEHRA,ÖZEN MEHMET,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN,TOPÇUOĞLU PERVİN
• NGS TÜM SEÇENEKLERİ TÜKETMİŞ NÜKS VE DİRENÇLİ MM HASTALARINDA ENDİKASYON DIŞI TEDAVİ OLUŞTURMADA REHBERLİK EDEBİLİR Mİ? - CENGİZ SEVAL GÜLDANE, KUZU IŞINSU, YÜKSEL SEHER, KAYGUSUZ GÜLŞAH, DALVA KLARA, ÖZCAN MUHİT, BEKSAÇ MERAL
• Evaluation of chemokine reseptor 4 expression by 68Ga Pentixafor PET/CT in patients with multiple myeloma - ÖZKAN ELGİN, SOYDAL ÇİĞDEM, ŞAHİN UĞUR, KÜÇÜK NURİYE ÖZLEM, BEKSAÇ MERAL, ÖZTÜRK CEMALEDDİN, TOPÇUOĞLU PERVİN, KROPF SASKIA, HANS JURGEN WESTER
• Large Unstained Cell Percentage as a Predictor of Efficacious Peripheral Stem Cell Mobilization - MERTER MUSTAFA,KÖKEN KÜBRA,YÜKSEL MERVE,NURDAN DEMİR ELİF,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,YÜKSEL MELTEM
• A biosimilar G-CSF filgrastim is as effective as a reference drug, however, it is not as cost effective as it supposed to be - PEKCAN GÜLTEKİN, KURT YÜKSEL MELTEM, ŞAHİN UĞUR, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, İLHAN OSMAN, DEMİRER TANER, GÜRMAN GÜNHAN, BEKSAÇ MERAL
• Engrafmanın Erken Belirteci: Büyük Boyanmamış Hücreler - Aydın Tolga,MERTER MUSTAFA,ŞAHİN UĞUR,Pekcan Gültekin,NARLI ÖZDEMİR ZEHRA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN,YÜKSEL MELTEM
• Evaluation of chemocine reseptor 4 expression by 68Ga pentixafor PET/CT in patients with multiple myeloma - ÖZKAN ELGİN,SOYDAL ÇİĞDEM,ŞAHİN U,KÜÇÜK NURİYE ÖZLEM,BEKSAÇ MERAL,ÖZTÜRK C,CİVRİZ BOZDAĞ SİNEM,TOPÇUOĞLU PERVİN
• Multiple myeloma - Frontline therapy - BEKSAÇ MERAL
• The management of R/R multiple myeloma patients - BEKSAÇ MERAL
• DM6-1 Response in Multiple Myeloma - BEKSAÇ MERAL
• Post-Induction Undetectable Minimal Residual Disease at 10-5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk - CENGİZ SEVAL GÜLDANE, DALVA KLARA, ÖZ D.,, BAKANAY SM, SOYDAN E.,, GÜRMAN GÜNHAN, İLHAN OSMAN, BEKSAÇ MERAL
• Ülkemiz Ailesel Miyelom Olgularında Saptanan Varyantlar :RAG2, CBL, APC ve PTCH1 Genleri - AKKUŞ E.,, TUNCALİ T.,, AYDIN Y.,, BEŞIŞIK S.,, BEKSAÇ MERAL
• Hastalık biyolojisinde güncel gelişmeler - BEKSAÇ MERAL
• Kordon Kanı Kök Hücre ve Natural Killer Hücre Ekspansiyonu - BEKSAÇ MERAL
• Plasma cell disorders subcommittee projects presentation - BEKSAÇ MERAL
• IMID’LERDE ARTAN GÜÇ: POMALIDOMID - BEKSAÇ MERAL
• Treatment with BiTEs: Is it the new standard for penta-refractory patients? - BEKSAÇ MERAL
• Response in Multiple Myeloma - BEKSAÇ MERAL
• Therapy of elderly patients - BEKSAÇ MERAL
• Multiple Miyelom - BEKSAÇ MERAL
• Scoring system for Auto-HCT: feasibility in MM patients - BEKSAÇ MERAL
• Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch–Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network - MAİ EK, HİELSCHER T.,, ZWEEGMAN S.,, BEKSAÇ MERAL, Dimopoulos MA, WEİSEL K.,, Cavo M.,, Sonneveld P.,, GOLDSCHMİDT H.,
• Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease - RİCHTER J.,, Laubach JP, STRİCKER S.,, Schjesvold FH, COHAN D.,, SUREDA A.,, MARANDA EL, BEKSAÇ MERAL, Dimopoulos MA, CHARİ A.,, Richardson PG, Moreau P.,
• Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study - Comenzo R.,, Palladini G.,, Kastritis E.,, Minnema MC, Wechalekar AD, Jaccard A.,, Dispenzieri A.,, Schonland S.,, Cibeira MT, BEKSAÇ MERAL, Hungria V.,, Vermeulen J.,, Merlini G.,
• Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT - GAGELMANN N.,, Eikema DJ, KOSTER L.,, NETELENBOS T.,, McDonald A.,, STOPPA AM, Anagnostopoulos A.,, BEKSAÇ MERAL, Schonland S.,, Yakoub-Agha I.,
• Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study - Sonneveld S.,, Terpos E.,, Boccadoro M.,, Delimpasi S.,, BEKSAÇ MERAL, Katodritou E.,, Mateos MV, Dimopoulos MA
• A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party - BEKSAÇ MERAL, LACOBELLİ S.,, KOSTER L.,, Cornelissen JJ, Griskevicius L.,, Engelhardt M.,, Elmaagacli A.,, Hayden A.,, Schonland S.,, Yakoub-Agha I.,
• Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE) - KİM K.,, Schutz NP, YEH SP, VERBURGH E.,, INT M.,, Alsharif F.,, Wu C.,, WAN H.,, HUANG Z.,, BEKSAÇ MERAL
• Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO. - Terpos E.,, Dimopoulos MA, Boccadoro M.,, Delimpasi S.,, BEKSAÇ MERAL, Katodritou E.,, Moreau P.,, Baldini L.,, Mateos MV, Einsele H.,, Sonneveld P.,
• Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial - WEİSEL K.,, Dimopoulos MA, Oriol A.,, BEKSAÇ MERAL, Dimopoulos F.,, LİBERATİ AM, Andersen LD, LAROCCA A.,, GROTE T.,, PELUSO T.,, Richardson PG
• Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma - CHARİ A.,, Dimopoulos MA, BEKSAÇ MERAL, LELEU X.,, WEİSEL K.,, RİCHTER J.,, DİRNBERGER F.,, İSKANDER K.,, Yusuf A.,, MİKHAEL J.,
• The Role Of Upfront Autotransplantatıon And Consolıdatıon Therapy In Newly Dıagnosed Multıple Myeloma (Ndmm): Fınal Analysıs Of The Randomızed Phase 3 Emn02/Ho95 Study - Cavo M.,, GAY F.,, BEKSAÇ MERAL, Dimopoulos MA, PANTANİ L.,, ZWEEGMAN S.,, ZAMAGNİ E.,, PALUMBO GA, Zambello R.,, Andersen NF, Boccadoro M.,, Sonneveld P.,
• Immunoglobulin V(D) J Recombination, Protein Ubiquitination, Cell Adhesion and Sonic Hedgehog Gene Variants are detected among familial Multiple Myeloma subjects following whole exome sequencing - AKKUŞ E.,, TİMUR T.,, AYDIN Y.,, BEŞIŞIK SK, GURKAN E.,, RATİP S.,, SALİHOĞLU A.,, SARGIN D.,, A., UNAL, TURCAN A.,, BEKSAÇ MERAL
• Trends in Autologous Stem Cell Mobilisation Practices in Myeloma Patients in Ebmt Centers Between 2008 And 2017 - DİLLON J.,, Hayden PJ, Eikema DJ, KOSTER L.,, Blaise D.,, HUANG H.,, BEKSAÇ MERAL, Schonland S.,, Yakoub-Agha I.,
• Autologous Hematopoietic Cell Transplantation For Relapsed Multiple Myeloma Performed With Stem Cells Re-Mobilised Following A Prior AUTO-HCT - A Retrospective Study on Behalf of EBMT CMWP - Drozd-Sokolowska J.,, GRAS L.,, ZİNGER N.,, MUTLU ARAT, BAŞAK G.,, GÜRMAN GÜNHAN, Hayden P.,, BEKSAÇ MERAL, Schonland S.,, Yakoub-Agha I.,
• COVID-19 Pandemisinde Allojeneik Hematopoetik Hücrelerin Kriyoprezervasyonu - KIRCALİ E.,, Öztürk C.,, YILMAZ H.,, YILDIRIM Y.,, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, TOPÇUOĞLU PERVİN, İLHAN OSMAN, BEKSAÇ MERAL, GÜRMAN GÜNHAN, YÜKSEL MELTEM KURT
• Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients - KIRCALİ EKİN, SEVAL GÜLDANE CENGİZ, ÖZTÜRK C.,, BOZDAĞ S.C., YÜKSEL MELTEM KURT, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, İLHAN OSMAN, GÜRMAN GÜNHAN, BEKSAÇ MERAL
• Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM) - Richardson pg, Perrot A.,, San-Miguel J.,, BEKSAÇ MERAL, LELEU X., Anderson KC
• Multipl Miyelomda Otolog Priferik Kök Hücre Nakli Sonrası Erken Nüksü Belirlemede CIBMTR, ISS ve R-ISS Skorlama Sistemlerinin Karşılaştırılması - SEVAL GÜLDANE CENGİZ, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM KURT, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, İLHAN OSMAN, GÜRMAN GÜNHAN, BEKSAÇ MERAL
• SUBCUTANEOUS DARATUMUMAB ± BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE in patients with newly diagnosed light chain amyloidosis: Updated results from the phase 3 andromeda study - Kastritis E.,, Sanchorawala V.,, Palladini G.,, Minnema MC, Wechalekar AD, Jaccard A.,, Dispenzieri A.,, Lee HC, Bhutani D.,, Gibbs S.,, Mollee P.,, Venner C.,, Lu J.,, Schönland S.,, Gatt M.,, Suzuki M.,, Kim K.,, Cibeira MT, BEKSAÇ MERAL, Libby E.,, Valent J.,, Hungria V.,, Wong SW, Rosenzweig M.,, Bumma N.,, Chauveau D.,, Tran N.,, Qin X.,, Vasey S.Y.,, Tromp B.,, Weiss W.,, Vermeulen J.,, Comenzo RL., Merlini G.,
• Molecular Alterations Obtained by High Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targetted Therapies - KUZU IŞINSU, SEVAL GÜLDANE CENGİZ, YÜKSEL S.,, Kaygusuz G.,, DALVA KLARA, ÖZCAN MUHİT, BEKSAÇ MERAL
• Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO. - Terpos E.,, Dimopoulos MA, Boccadoro M.,, Delimpasi S.,, BEKSAÇ MERAL, Katodritou E.,, Moreau P.,, Baldini L.,, Symeonidis A.,, Bila J.,, Oriol A.,, Mateos MV, Einsele H.,, Orfanidis L.,, Gries KS, Fastenau J.,, Kampfenkel T.,, Qiu Y.,, Amin H.,, Sonneveld P.,
• Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM). - Richardson PG.,, Perrot A.,, San-Miguel J.F.,, BEKSAÇ MERAL, Spicka I.,, Cavo M.,, Prince M.,, Zheng C.,, Dubin F.,, Van De Velde H.,, Anderson K.C.,
• Assocıatıon Of Reduced Absolute İflc And Dflc Wıth Prolonged Major Organ Deterıoratıon Progressıon-Free Survıval In Patıents Wıth Newly Dıagnosed Al Amyloıdosıs Receıvıng VCD Wıth Or Wıthout Daratumumab: Results From Andromeda - Kastritis E.,, Comenzo R.,, Minnema MC, Wechalekar A.,, Jaccard A.,, Sanchorawala W.,, Lee H.C.,, Gibbs S.,, Mollee P.,, Venner CP, Schoenland S.,, BEKSAÇ MERAL, Bumma N.,
• Melfelan Hazırlık Rejimi Tek Gün Ve İki Gün Kullanımı Yan Etki Değerlendirmesi, Fark Var Mı ? - Öztürk N.,, BEKLER İ.,, ERDEMSOY B.,, ŞEN T.,, SEVAL GÜLDANE CENGİZ, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, TOPÇUOĞLU PERVİN, BEKSAÇ MERAL, GÜRMAN GÜNHAN, YÜKSEL MELTEM
• In Vitro Semisolid Agar Veya Sıvı Kültür Koşullarında Vpa Ve Nam Gibi Küçük Moleküller Aracılığı İle Hematopoietik Kök Hücre Ekspansiyonu Kinetikleri - DALVA KLARA, AKIN Hasan Yalım, ÖNCÜL EMİNE BEGÜM GENCER, TURASAN EYLÜL, YOUSEFZADEH MAHSA, ŞEKER E.,, SÜT HASAN, ÇAĞAN M.,, YURDAKUL MESUTOĞLU PINAR, BEKSAÇ MERAL
• Fare-İnsan Xenograft Hematopoietik Kök Hücre Nakli Modelinde Vpa Ve/Veya Nam İle Ekspande Edilmiş Hematopoietik Kök Hücrelerin Engrafman Kinetikleri - TURASAN EYLÜL, ÖNCÜL EMİNE BEGÜM GENCER, AKIN Hasan Yalım, YOUSEFZADEH MAHSA, ÇAĞAN M.,, SEVAL M.,, DALVA KLARA, YURDAKUL MESUTOĞLU PINAR, BEKSAÇ MEHMET SİNAN, BEKSAÇ MERAL
• Allojenik Kök Hücre Nakli Hastalarında Peritransplant Metronidazol Kullanımıyla Akut GVHD Riskinin İlişkisi - KIRCALİ EKİN, SEVAL GÜLDANE CENGİZ, Öztürk C.,, CİVRİZ BOZDAĞ SİNEM, YÜKSEL MELTEM KURT, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, İLHAN OSMAN, BEKSAÇ MERAL, GÜRMAN GÜNHAN, TOPRAK SELAMİ KOÇAK
• Solid Organ Nakli Ve Allojenik Kök Hücre Nakli Sonrası Gelişen Post-Transplant Lenfoproliferatif Hastalık- Tek Merkez Deneyimi - Öztürk C.,, KIRCALİ EKİN, KOYUN DERYA, YILMAZ H.,, YAVUZ G.,, KARAKAYA B.,, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM KURT, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, GÜRMAN GÜNHAN, BEKSAÇ MERAL, CİVRİZ BOZDAĞ SİNEM, İLHAN OSMAN
• Relaps/Refrakter Hodgkin Lenfoma Hastalarında Allojenik Hematopoetik Kök Hücre Nakli: Tek Merkez Deneyimi - KOYUN D.,, ŞAHİN U.,, SEVAL GÜLDANE CENGİZ, CİVRİZ BOZDAĞ SİNEM, TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM KURT, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, DEMİRER TANER, BEKSAÇ MERAL, İLHAN OSMAN, GÜRMAN GÜNHAN, ÖZCAN MUHİT
• Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University - SEVAL GÜLDANE CENGİZ, BOZDAĞ S.C., TOPRAK SELAMİ KOÇAK, YÜKSEL MELTEM KURT, TOPÇUOĞLU PERVİN, ARSLAN ÖNDER, ÖZCAN MUHİT, DEMİRER TANER, İLHAN OSMAN, TUNCALİ T.,, GÜRMAN GÜNHAN, BEKSAÇ MERAL
• Treatment of Patients With Relapsed/Refractory Multiple Myeloma With Pomalidomide and Dexamethasone With or Without Subcutaneous Daratumumab: Patient-Reported Outcomes From APOLLO - Dimopoulos MA, Terpos E.,, Boccadoro M.,, Delimpasi S.,, BEKSAÇ MERAL, Katodritou E.,, Moreau P.,, Baldini L.,, Mateos MV, Einsele H.,, Orfanidis I.,, Sonneveld P.,
• Large Unsatained Cell (LUC) percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation - MERTER MUSTAFA,KÖKEN KÜBRA,YÜKSEL MERVE,DEMİR NURDAN,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,YÜKSEL MELTEM
• Heparin enhances CD34 content of stem cells collected following G-CSF +/- chemotherapy - MERTER MUSTAFA,ŞAHİN UĞUR,YILDIRIM Y,,İLHAN OSMAN,BEKSAÇ MERAL
• A Biosimiliar G-CSF filgrastim is as effective as a reference drug however it is not cost effective as supposed to be and by the way no impact on the health care system - YÜKSEL MELTEM,PEKCAN GÜLTEKİN,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,GÜRMAN GÜNHAN,BEKSAÇ MERAL
• Evalauting peritransplant albümin decline as a predictor os acute graft versus host disease - MERTER MUSTAFA,YÜKSEL MELTEM,NURDAN DEMİR ELİF,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
• Condıtıonıng Wıth Bortezomıb-Mel200 In Comparıson To Mel200 Improves Survıval Among Myeloma Patıents In≤Pr Prıor To Auto-Hct: A Study From The Cmwp Of The Ebmt - BEKSAÇ MERAL,Eikema DJ,Chevallier P,,Hulin C,,Orchard K,,Mohty M,,Hamladji RM,Spyridonidis A,,Schönland S,,Agha IY
• Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95) - Sonneveld P,,BEKSAÇ MERAL,Holt BVD,Dimopoulos MA,Carella AM,Ludwig H,,Zweegman S,,Wester R,,Hajek R,,L, Pantani,Fioritoni F,,Mellqvist UH,Troia R,,Andersen NF,Wu KL,Carvalho S,,Croockewit AJ,Schjesvold F,,Offidani M,,M, Cavo,Boccadoro M,
• Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type A Study from the Chronic Malignancies Working Party of the EBMT - Sahebi F,,Eikema DJ,Koster L,,Meijer E,,Angelucci E,,Tarella D,,McDonald A,,BEKSAÇ MERAL,S, Schonland
• Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda - Comenzo RL,Kastritis E,,Palladini G,,Minnema MC,Wechalekar AD,Jaccard A,,Sanchorawala V,,Mollee P,,Venner CP,,Schönland S,,Gatt M,,Suzuki K,,Cibeira MT,BEKSAÇ MERAL,Libby E,,Valent J,,Hungria VTM,Wong SW,Rosenzweig M,,Chauveau D,,Dimopoulos MA,Vasey SY,Tromp B,,Weiss BM,Vermeulen J,,Merlini G,
• Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT - Vincent L,,Ceballos P,,J, Finke,Passweg J,,Minnema MC,Ducastelle S,,Schroyens W,,Zuckerman T,,Ladetto M,,BEKSAÇ MERAL
• Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study - Sanchorawala V,,Palladini G,,Minnema MC,Jaccard A,,BEKSAÇ MERAL,Hungria VTM,Rosenzweig M,,Vermeulen J,,Wechalekar AD
• Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Soft-Tissue Plasmacytomas: Icaria-MM Subgroup Analysis - BEKSAÇ MERAL,Richardson PG,Unal A,,Corradini P,,DeLimpasi S,,Z, Gulbas,Kerridge IH,Symeonidis A,,Bringhen S,,Moreau P,,Spicka I,
• Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Dimopoulos MA,Terpos E,,Boccadoro M,,Delimpasi S,,BEKSAÇ MERAL,Katodritou E,,P, Moreau,L, Baldini,A, Symeonidis,Oriol A,,Mateos MV,Einsele H,,Orfanidis I,,Ahmadi T,,Ukropec J,,Kampfenkel T,,Schecter J,,Qiu Y,,Amin H,,Vermeulen J,,Carson J,,Sonneveld P,
• Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study - Laubach JP,Schjesvold F,,Mariz M,,Dimopoulos MA,Marada EL,Spicka I,,Hungria VTM,Shelekhova T,,Abdo A,,Jacobasch L,,BEKSAÇ MERAL,Goncalves I,,Lonial S,,Spencer A,,Blanche PM,Moreau P,,Richardson PG,SanMiguel JF
• Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study - Cavo M,,Gay F,,BEKSAÇ MERAL,Dimopoulos MA,Pantani L,,Petrucci MT,Dozza L,,Maisnar V,,Hansson M,,Belotti A,,Pour L,,Ypma PF,M, Grasso,Croockewit S,,Musto P,,Ludwig H,,Morelli AM,Hajek R,,Driessen U,,Gimsing P,,Mellqvist UH,Zander T,,Boccadoro M,,Sonneveld P,
• Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized PANORAMA 3 Study - Laubach JP,Schjesvold F,,Mariz M,,Dimopoulos MA,LechMaranda E,,Spicka I,,Hungria VTM,Shelekhova T,,Abdo A,,Jacobasch L,,Polprasert C,,Hajek R,,Illes A,,Wrbel T,,Sureda A,,BEKSAÇ MERAL,Gonçalves IZ,Creixenti JB,Rajkumar SV,Chari A,,Lonial S,,Spencer A,,Moreau P,,Richardson PG,JF SanMiguel
• Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies - KUZU IŞINSU,CENGİZ SEVAL GÜLDANE,YÜKSEL MELTEM,KAYGUSUZ GÜLŞAH,DALVA KLARA,ÖZCAN MUHİT,BEKSAÇ MERAL
• LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTEMYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS -A RETROSPECTIVE STUDY FROM A TERTIARY CENTER - CENGİZ SEVAL GÜLDANE,USLU ATİLLA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,İLHAN OSMAN
• Pre-Transplant Hemoglobın And Serum Creatınıne Levels Correlate Wıth Progressıon Free Survıval In Myeloma Patıents Undergoıng Autologous Stem Cell Transplantatıon - CENGİZ SEVAL GÜLDANE,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
• A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Isatuximab, Pomalidomide, and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed / Multiple Myeloma Refractory (RRMM) - Richardson PG,Attal M,,Rajkumar V,,SanMiguel J,,BEKSAÇ MERAL,Spicka I,,Leleu X,,Schjesvold F,,Moreau P,,Dimopoulos MA,Minarik J,,Cavo M,,Mace S,,Prince HM,Corzo KP,Campana F,,LeGuennec S,,F, Dubin
• Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center - CENGİZ SEVAL GÜLDANE,ÖZTÜRK N,,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
• Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM - Schjesvold F,,Dimopoulos MA,BEKSAÇ MERAL,Oriol A,,Lindsay J,,Liberati AM,Robak P,,Weisel K,,Larocca A,,Yagci M,,Vural F,,Anderson LD,Srinivasan S,,Grote L,,Biyukov TN,Richardson PG
• Ixazomıb Vs Placebo As Post-Inductıon Maıntenance Therapy In Newly Dıagnosed Multıple Myeloma (Ndmm) Patıents (Pts) Not Undergoıng Autologous Stem Cell Transplant (Asct): Phase 3 Tourmalıne-Mm4 - Dimopoulos MA,Spika I,,Quach H,,Oriol A,,Hjek R,,Garg M,,BEKSAÇ MERAL,Bringhen S,,Katodritou E,,Chng WJ,Leleu X,,Iida S,,Mateos MV,Morgan G,,Labotka R,,Wang B,,Palumbo A,,Lonial S,
• A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm - ÖZCAN MUHİT,KOYUN DERYA,CENGİZ SEVAL GÜLDANE,USLU ATİLLA,KIRCALİ EKİN,ÖZTÜRK CEMALETTİN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,İLHAN OSMAN,BEKSAÇ MERAL
• Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001 - Leleu X,,BEKSAÇ MERAL,Chou T,,Dimopoulos MA,Yoon SS,Prince HM,Pour L,,Shelekhova T,,Chari A,,Khurana M,,Obreja M,,Qi M,,Oriol A,,Samuel D,,Siegel D,
• Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001 - Leleu X,,BEKSAÇ MERAL,Chou T,,Dimopoulos MA,Yoon SS,Prince HM,Pour L,,Shelekhova T,,Chari A,,Khurana M,,Obreja M,,Qi M,,Oriol A,,Samuel D,,Siegel D,
• Pomalıdomıde, Bortezomıb, Dexamethasone After 1 Prıor Lıne Of Therapy In Patıents Wıth Relapsed Or Refractory Multıple Myeloma And Renal Impaırment: Optımısmm Subanalysıs - Schjesvold F,,Dimopoulos MA,BEKSAÇ MERAL,Oriol A,,Lindsay J,,Liberati AM,Galli M,,Robak P,,Weisel K,,Larocca A,,Yagci M,,Vural F,,Anderson LD,Kanate AS,Casal E,,Jiang R,,Srinivasan S,,Grote L,,Biyukov T,,Richardson P,
• Pomalıdomıde, Bortezomıb, Dexamethasone After 1 Prıor Lıne Of Therapy In Patıents Wıth Relapsed Or Refractory Multıple Myeloma And Renal Impaırment: Optımısmm Subanalysıs - Schjesvold F,,Dimopoulos MA,BEKSAÇ MERAL,Oriol A,,Lindsay J,,Liberati AM,Galli M,,Robak P,,Weisel K,,Larocca A,,Yagci M,,Vural F,,Anderson LD,Kanate AS,Casal E,,Jiang R,,Srinivasan S,,Grote L,,Biyukov T,,Richardson P,
• Isatuxımab Plus Pomalıdomıde And Dexamethasone In Patıents Wıth Relapsed/Refractory Multıple Myeloma And Soft-Tıssue Plasmacytomas: Icarıa-Mm Subgroup Analysıs - BEKSAÇ MERAL,Richardson PG,Unal A,,Corradini P,,DeLimpasi S,,Gulbas Z,,Kerridge I,,Mikala G,,Neylon A,,Symeonidis A,,Bringhen S,,Moreau P,,Velde H,,Campana F,,Guennec SL,I, Spicka
• Subcutaneous Daratumumab Cyclophosphamıde, Bortezomıb, And Dexamethasone (Cybord) In Patıents Wıth Newly Dıagnosed Lıght Chaın (Al) Amyloıdosıs: Prımary Results From The Phase 3 Andromeda Study - Kastritis E,,Palladini G,,Minnema MC,Wechalekar AD,Jaccard A,,Lee HC,Sanchorawala V,,Gibbs S,,Mollee P,,Venner CP,Lu J,,Schonland S,,Gatt ME,Suzuki K,,Kim K,,Cibeira MT,BEKSAÇ MERAL,Libby E,,Valent J,,Hungria V,,Wong SV,Rosenzweig W,,Bumma N,,Chauveau D,,Ahmadi T,,Tran N,,Qin X,,Vasey SY,Tromp B,,Schecter JM,Weiss BM,Vermeulen J,,Merlini G,,Comenzo RL
• Ixazomıb Vs Placebo As Post-Inductıon Maıntenance Therapy In Newly Dıagnosed Multıple Myeloma (Ndmm) Patıents (Pts) Not Undergoıng Autologous Stem Cell Transplant (Asct): Phase 3 Tourmalıne-Mm4 Trıal - Dimopoulos MA,Spicka I,,Quach H,,Oriol A,,Hajek R,,Garg M,,BEKSAÇ MERAL,Bringhen S,,Katodritou E,,WJ Chng,Leleu X,,Iida S,,Mateos MV,Morgan G,,Vorog A,,Labotka R,,Wang B,,A, Palumbo,Lonial S,
• How should we position immunotherapies in the changing paradigm of myeloma treatment? - BEKSAÇ MERAL
• Updates and study issues - BEKSAÇ MERAL
• Extramedullary myeloma: an unmet need - BEKSAÇ MERAL
• How to manage myeloma patients during a pandemic ? - BEKSAÇ MERAL
• How to manage myeloma patients during a pandemic? - BEKSAÇ MERAL
• COVID 19 Pandemisinde Myelom Yönetimi ve Oral Tedaviler - BEKSAÇ MERAL
• Immunomodülatuar İlaçlar ve Multiple Myeloma - BEKSAÇ MERAL
• COVID 19 Pandemisinde Myelomda Oral Tedaviler - BEKSAÇ MERAL
• Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. - Durie BG,Moreau P,,Sonneveld P,,BEKSAÇ MERAL,Kumar S,
• Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial) - Sonneveld P,,BEKSAÇ MERAL,Dimopoulos MA,Ludwig H,,Driessen C,,Wester R,,Hajek R,,S, Croockewit
• Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial) - Sonneveld P,,BEKSAÇ MERAL,Dimopoulos MA,Ludwig H,,Driessen C,,Wester R,,Hajek R,,S, Croockewit
• Risk assessment at diagnosis and risk based therapy - BEKSAÇ MERAL
• Update on multiple myeloma - BEKSAÇ MERAL
• Monoclonal Antibodies in Newly Diagnosed Multiple Myeloma: New Trials and Combinations - BEKSAÇ MERAL
• Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. - Palumbo A,,Weisel K,,Nooka AK,BEKSAÇ MERAL,Spicka I,,VTM Hungria,Mateos MA,TM Mark
• Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. - Palumbo A,,Weisel K,,Nooka AK,BEKSAÇ MERAL,Spicka I,,VTM Hungria,Mateos MA,TM Mark
• Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. - Palumbo A,,Weisel K,,Nooka AK,BEKSAÇ MERAL,Spicka I,,VTM Hungria,Mateos MA,TM Mark
• Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. - Palumbo A,,Weisel K,,Nooka AK,BEKSAÇ MERAL,Spicka I,,VTM Hungria,Mateos MA,TM Mark
• TREATMENT OF MYELOMA:MAİNTENANCE STRATEGY - BEKSAÇ MERAL
• İnternational representative - BEKSAÇ MERAL
• Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients community-based trial data - BEKSAÇ MERAL
• Double ASCT: Suitable for all patients - BEKSAÇ MERAL
• The viewpoint of Scientific Groups: Part 2 - BEKSAÇ MERAL
• Current Immunotherapies - BEKSAÇ MERAL
• Myeloma - BEKSAÇ MERAL
• Relapsed myeloma - BEKSAÇ MERAL
• Multiple Myeloma - BEKSAÇ MERAL
• Türkiye’de erişilebilir yeni tedaviler ve klinik araştırmalar - BEKSAÇ MERAL
• Multıple Myeloma ve Plazma Hücre Hastalıkları - BEKSAÇ MERAL
• Multiple Myeloma - the Best Therapy for newly diagnosed patients in 2019 - BEKSAÇ MERAL
• A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) - Richardson PG,Attal M,,Rajkumar SV,San Miguel J,,BEKSAÇ MERAL,Spicka I,,Leleu X,,Schjesvold F,,Moreau P,,Dimopoulos MA,Huang JSY,Minarik J,,Cavo M,,Prince HM,Mace S,,Corzo KP,Campana F,,LeGuennec S,,Dubin F,,Anderson KC
• Analysis of outcomes in patients with myeloma who had a second allohct EITHER for disease relapse or graft failure: AN EBMT CMWP study - Hayden P,,Eikema DJ,de Wreede L,,Koster L,,Kroger N,,Einsele H,,Petersen E,,Angelucci E,,Potter M,,Passweg J,,Espiga CR,Leblond V,,Platzbecker U,,Tischer J,,Ciceri F,,Veelken JH,Ljungman P,,Schaap N,,Milpied N,,Carella AM,Gandemer V,,Arcese W,,Bloor A,,Olivieri A,,Vincent L,,BEKSAÇ MERAL,Schonland S,,YakoubAgha I,
• Multiple myeloma treatment in real-world clinical practice: A focus on induction regimens prior to autologous stem cell transplantation from the prospective, multinational, non-interventional emmos study - Mohty M,,Terpos E,,Mateos MV,Cavo M,,Lejniece S,,BEKSAÇ MERAL,Legiec W,,Bekadja MA,M, Dimopoulos,Stankovic S,,Duran MS,De Stefano V,,Corso A,,Kochkareva Y,,Laane E,,Berthou C,,Salwender H,,Masliak Z,,Peceliunas V,,Willenbacher W,,Silva J,,Louw V,,Nemet D,,Borbenyi Z,,Abadi U,,Pedersen RS,Cernelc P,,Potamianou A,,Couturier C,,Feys C,,ThoretBauchet F,,Boccadoro M,
• Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT - Schönland SO,Iacobelli S,,Koster L,,Blaise D,,Potter M,,Cornelissen JJ,Chevallier P,,Mayer J,,Remnyi P,,Gribben JG,Meijer E,,Carpenter B,,Collin MP,GeddeDahl T,,Potter V,,Malladi R,,Stelljes M,,Bloor A,,TUĞLULAR AYŞE TÜLİN,Weissinger F,,BEKSAÇ MERAL,Hayden PJ,YakoubAgha I,,Kröger N,
• A Phase 3 Randomızed, Open-Label, Multıcenter Study Of Isatuxımab, Pomalıdomıde, And Low-Dose Dexamethasone Vs Pomalıdomıde And Low-Dose Dexamethasone In Relapsed/Refractory Multıple Myeloma (Rrmm) - Attal M,,Richardson PG,Rajkumar SV,SanMiguel J,,BEKSAÇ MERAL,Spicka I,,Leleu X,,Schjesvold F,,Moreau P,,Dimopoulos MA,Huang JSY,Minarik J,,Cavo M,,Prince HM,Mace S,,Corzo KP,Campana F,,LeGuennec S,,Dubin F,,Anderson KC
• Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial - Dimopoulos MA,Weisel K,,Lonial S,,White D,,Moreau P,,Mateos MV,SanMiguel J,,Anderson KC,O, Shpilberg,Grosicki S,,Spicka I,,WalterCroneck A,,Magen H,,Belch A,,Reece D,,BEKSAÇ MERAL,Ganetsky A,,Jou YM,McKiver MP,Singhal AK,Richardson PG
• Prognostic value of post-induction PET/CT in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT) - BEKSAÇ MERAL,zamagni e,,TM MARK,NANNİ C,,JAGANNATH S,
• RETROSPECTIVE ANALYSIS OF 149 UNSELECTED PATIENTSWITH MANTLE CELL LYMPHOMA CONFIRMS PROGNOSTICRELEVANCE OF MIPI: SINGLE CENTER EXPERIENCE - SEVAL GÜLDANE CENGİZ,ULAŞ BELİZ BAHAR,bolat bugu,Taşçı Onur,karatepe fulya,KUZU IŞINSU,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ÖZCAN MUHİT,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,ARSLAN ÖNDER
• Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients – the Diadem Study from the Chronic Malignancies Working Party of the EBMT - Anna WG,Wang J,,Wreede LC,Sirait T,,ÖZKURT ZÜBEYDE NUR,Snowden JA,Dreger P,,Ills A,,ARAT MUTLU,Bulabois CE,Baurmann H,,Sever M,,Basak GW,Nikolousis M,,Potter V,,Schroyens W,,Gyan E,,Gorkom GV,Serna J,,Guffroy B,,Hayden PJ,BEKSAÇ MERAL,Schönland SO,YakoubAgha I,
• Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT? - YÜKSEL MELTEM,CENGİZ SEVAL GÜLDANE,USLU ATİLLA,KIRCALI EKİN,ÖZTÜRK CEMALEDDİN,NARLI ÖZDEMİR ZEHRA,CINAR GÜLE,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AZAP ALPAY,AKAN HAMDİ,BEKSAÇ MERAL
• Multiple Myelom Hastalarında Otolog Periferik Kök Hücre Nakli Esnasında Gelişen Nötropenik Ateş - USLU ATİLLA,CENGİZ SEVAL GÜLDANE,ÖZTÜRK C,,NARLI ÖZDEMİR ZEHRA,KIRCALİ EKİN,KOYUN DERYA,TOPÇUOĞLU PERVİN,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,İLHAN OSMAN,BEKSAÇ MERAL,ÖZCAN MUHİT,ARSLAN ÖNDER,GÜRMAN GÜNHAN,DEMİRER TANER,YÜKSEL MELTEM
• İyi Riskli Aml’de İkinci Tam Remisyonda Allojeneik Hematopoietik Kök Hücre Nakli Tek Merkez Deneyimi - PEKCAN GÜLTEKİN,NARLI ÖZDEMİR ZEHRA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Miyelom Hastalarında Ohkhn Öncesi Kullanılan İlaçların Cmv Reaktivasyonu Üzerine Sağkalımı Azaltıcı Etkisi Olabilir mi? - YÜKSEL MELTEM,CENGİZ SEVAL GÜLDANE,USLU ATİLLA,KIRCALİ EKİN,KOYUN DERYA,ÖZTÜRK CEMALETTİN,NARLI ÖZDEMİR ZEHRA,ÇINAR GÜLE,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AZAP ALPAY,AKAN HAMDİ,BEKSAÇ MERAL
• Autologous Stem Cell Transplantatıon Versus Bortezomıb-Melphalan-Prednısone For Newly Dıagnosed Multıple Myeloma Patıents: Fınal Analysıs Of The Phase 3 Emn02/Ho95 Study - Pantani L,,Hajek R,,GAY F,,BEKSAÇ MERAL,Dozza L,,Johnsen HE,Petrucci MT,Mellqvist UH,Conticello C,,Driessen C,,Mancuso K,,Marzocchi G,,Dimopoulos MA,Zweegman S,,Zamagni E,,Wu KL,Gamberi B,,Crippa C,,Van der Holt B,,Offidani M,,Wester R,,Vincelli ID,Troia R,,Cornelisse P,,Boccadoro M,,Sonneveld P,,Cavo M,
• Allojeneik Kök Hücre Nakli Sonrası Akut Lösemi Hastalarında Nüksü Öngörmede Kimerizm İle Mrd Karşılaştırılması - CENGİZ SEVAL GÜLDANE,ULAŞ BELİZ BAHAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
• Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey - BEKSAÇ MERAL,CENGİZ SEVAL GÜLDANE,PAYDAŞ SEMRA,TUĞLULAR AYŞE TÜLİN,ARSLAN ÖNDER,GÖKER ALİ HAKAN,KAYNAR LEYLAGÜL,ALTUNTAŞ FEVZİ,ATALAY FİGEN,ÜSKÜDAR TEKE HAVA,BOLAMAN ALİ ZAHİT,PEHLİVAN MUSTAFA,SÖNMEZ MEHMET,DEMİR AHMET,TOPÇUOĞLU PERVİN,YILMAZ M,,KABUKÇU SH,ALBAYRAK M,,YURTTAŞ NO,SALİHOĞLU AYŞE,ÇAKAR MK,GÜRMAN GÜNHAN
• Transplant Sonrası Trombositopenide Eltrombopag: Tek Merkez Deneyimimiz - KIRCALİ EKİN,CENGİZ SEVAL GÜLDANE,KOYUN DERYA,CİVRİZ BOZDAĞ SİNEM,TOPÇUOĞLU PERVİN,ÖZCAN MUHİT,BEKSAÇ MERAL,İLHAN OSMAN,ARSLAN ÖNDER,GÜRMAN GÜNHAN,TOPRAK SELAMİ KOÇAK,DEMİRER TANER,AKAN HAMDİ,USLU ATİLLA,ÖZTÜRK C,,YÜKSEL MELTEM
• Impact of ABO mismatch on outcomes of allogeneic hematopoietic stem cell recipients: 30 years of experience with 1016 patients. - ATİLLA ERDEN,TOPÇUOĞLU PERVİN,AKKUŞ ERMAN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,DEMİRER TANER,ARSLAN ÖNDER,ÖZCAN MUHİT,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN,TOPRAK SELAMİ KOÇAK
• Refrakter Akut Lösemili Hastalarda Ardışık Kurtarma Tedavisi İle Birlikte Ahkhn Yeterli Kür Sağlayabilir mi? - CENGİZ SEVAL GÜLDANE,KIRCALİ EKİN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,TOPÇUOĞLU PERVİN
• T-All Hastalarında Allojeneik Hematopoetik Kök Hücre Nakli Sonrasında Nelarabin Tedavisi Graftı Kurtarabilir mi? - CENGİZ SEVAL GÜLDANE,USLU ATİLLA,NARLI ÖZDEMİR ZEHRA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,YÜKSEL MELTEM
• KRONİK MİYELOİD LOSEMİ (KML) HASTALARINDA KML KOKHUCRESİ BCR- ABL’DEN BAĞIMSIZ PROGNOSTİK BİR FAKTOR OLABİLİR Mİ? - İLHAN OSMAN,NARLI ÖZDEMİR ZEHRA,ARSLAN AYŞENUR,OKAY MÜFİDE,ipek şenay,DALVA KLARA,SAYDAM GÜRAY,HAZNEDAROĞLU İBRAHİM CELALETTİN
• Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation. - DEMİRER TANER,SEVAL GÜLDANE CENGİZ,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Maternal ve Fetal Serum Örneklerinde HematopoietikSitokinler Olan Kök Hücre Faktör (Stem Cell Factor=SCF)ve Granülosit Düzeylerinin ve in vitro Etkinliklerinin Karşılaştırılmalı Analizi - Akın Yalım,YURDAKUL MESUTOĞLU PINAR,katlan doruk cevdi,ÖRGÜL GÖKÇEN,BEKSAÇ MEHMET SİNAN,BEKSAÇ MERAL
• Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis - SEVAL GÜLDANE CENGİZ,Öztürk nergis,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
• Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/Relapsed or Refractory Multiple Myeloma - Leleu X,,BEKSAÇ MERAL,Mateos MV,Pour L,,Weisel K,,Coriu D,,Obreja M,,Goldrick A,,Dimopoulos M,
• Modulation of NK, T, B cell subpopulations by Pomalidomide predicts favorable progression-free survival (PFS): Results from a large randomized clinical trial in relapsed/refractory myeloma - RAO P,,SAMUR M,,TALLURİ S,,DEREBAİL S,,POTLURİ L,,HAAS E,,Buonopane M,,Heubeck A,,Fulciniti M,,LazoKallanian S,,Hong K,,Peluso T,,Daley J,,Biyukov T,,BEKSAÇ MERAL,Dimopoulos MA,Hussain M,,Pierceall W,,Richardson PG,Anderson KC,Thakurta A,,AvetLoiseau H,,Munshi N,
• Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM) - Kaiser M,,BEKSAÇ MERAL,Gulbrandsen N,,Schjesvold F,,Hajek R,,Moreau P,,Arriba F,,Mateos MV,West S,,Spencer A,,Rajkumar SV,Suryanarayan K,,Czorniak M,,Teng Z,,Labotka R,,Dimopoulos MA
• Ex Vıvo Expansıon Of Human Umbılıcal Cord Blood Hematopoıetıc Stem Cells Wıth Valproıc Acıdor Nıcotınamıde Is Able To Accelerate Engraftment In A Nsg Mouse Transplant Model - DİLEK Y,,AKIN HY,TURASAN E,,KARAKAYA H,,ÖZIŞIK MS,FADILOĞLU E,,TANACAN A,,YURDAKUL MESUTOĞLU PINAR,BEKSAÇ MERAL
• Effıcacy And Safety Of Daratumumab, Bortezomıb, And Dexamethasone (D-Vd) In Relapsed Or Refractory Multıple Myeloma (Rrmm): Updated Subgroup Analysıs Of Castor Based On Cytogenetıc Rısk - Weisel K,,Spencer A,,Lentzsch S,,AvetLoiseau H,,Mark TM,Spicka I,,Masszi T,,Lauri B,,Levin MD,Bosi A,,Hungria V,,Cavo M,,Lee JJ,Nooka A,,Quach H,,Munder M,,Lee C,,Barreto W,,Corradini P,,Min CK,ChananKhan AA,Horvath N,,Capra M,,BEKSAÇ MERAL,Ovilla R,,Jo JC,Shin HJ,Sonneveld P,,Soong D,,Casneuf T,,Chiu C,,Amin H,,Ukropec J,,Mateos MMV
• Sıgnıfıcant Pom Effect On The Immune-Cellprofıles In B, T And Nk Subsets In A Large Cohortclınıcal Trıal In Relapsed/Refractory Myeloma - Prabhala R,,Samur M,,Talluri S,,Stekla M,,Acharya S,,Yenumula C,,Nanjappa P,,Lopez M,,Buonopane M,,Heubeck A,,Fulciniti M,,Szalat R,,LazoKallanian S,,Hong K,,Peluso T,,Daley J,,Biyukov T,,Oriol Rocafiguera A,,BEKSAÇ MERAL,Dimopoulos M,,Hussain M,,Pierceall W,,Richardson P,,Anderson K,,Thakurta A,,AvetLoiseau H,,Munshi N,
• 1st INTERNATIONAL HEALTH SCIENCE and LIFE CONGRESS (IHSLC 2018) - AKÇORA YILDIZ DİLARA,ÖZKAN TÜLİN,BEKSAÇ MERAL,SUNGUROĞLU ASUMAN
• Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma - Hulin C,,Richardson PG,Attal M,,Goodman HJ,Doronin V,,Spicka I,,LeGuennec S,,Campana F,,van de Velde H,,BEKSAÇ MERAL
• Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017 - Hayden PJ,Eikema DJ,Koster L,,Goldschmidt H,,Blaise D,,Potter M,,Touzeau C,,Huynh A,,Byrne J,,Hulin C,,Rabin NK,Benjamin R,,Cornelissen JJ,Nahi H,,Cook G,,Gribben JG,Meijer E,,Remnyi P,,Mayer J,,Tsirigotis P,,Bernardeschi P,,BEKSAÇ MERAL,Schönland SO,YakoubAgha I,
• Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE) - Yeh Su PENG,Alsharif FAHAD,BEKSAÇ MERAL,Chen Wenming,Fantl Dorotea,Mitina TATİANA,Verburgh ESTELLE,Chng Wee Joo,Wu KwangWei,Zhang Zijing,Wan HUİ,Kim Kihyun
• ANTI-PD-1 Treatment in a Family with Constitutional Mismatch Repair Deficiency Syndrome with Multiple Cancers from Turkey. Is Cancer Immunoprevention with Checkpoint Inhibitors HAS a Role in CASES with Homozygous Mutationis - ÜNAL EMEL,ÖZYÖRÜK DERYA,TAÇYILDIZ NURDAN,PINARLI FERDA,ERDOĞAN A,,Hanalioglu S,,ERDEM ARZU,BEKSAÇ MERAL
• Clonal Plasma Cell Detectıon By Hıgh Sensıtıve Flow Cytometry In Aphaeresıs Product Is Poor Prognostıc And Not Increased By Use Of Plerıxafor Alone - CENGİZ SEVAL GÜLDANE,USLU A,,DALVA KLARA,BAKANAY SM,MERTER MUSTAFA,ŞAHİN UĞUR,İLHAN OSMAN,BEKSAÇ MERAL
• Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,USLU A,,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT - YÜKSEL MELTEM,CENGİZ SEVAL GÜLDANE,KİRCİLİ E,,D, KOYUN,ÖZTÜRK C,,NARLI ÖZDEMİR ZEHRA,ÇINAR G,,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AZAP A,,AKAN HAMDİ,BEKSAÇ MERAL
• Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT - YÜKSEL MELTEM,CENGİZ SEVAL GÜLDANE,KİRCİLİ E,,D, KOYUN,ÖZTÜRK C,,NARLI ÖZDEMİR ZEHRA,ÇINAR G,,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AZAP A,,AKAN HAMDİ,BEKSAÇ MERAL
• Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies - ARSLAN ÖNDER,ELÇİN AYŞE ESER,ATİLLA ERDEN,Şeker Şükran,Baydın Pınar,Gündüz Mehmet,ÖZEN MEHMET,Bayraktar Ulaş,İLHAN OSMAN,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: updated subgroup analysis of CASTOR - Weisel K,,Spencer A,,Lentzsch S,,AvetLoiseau H,,Mark TM,Spicka I,,Bosi A,,Hungria VTM,Cavo M,,Lee JJ,Nooka AK,Quach H,,Munder M,,BEKSAÇ MERAL,Sonneveld P,,Soong D,,Ukropec J,,Qi M,,Mateos MV
• A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) - Richardson PG,Attal M,,Rajkumar SV,San Miguel J,,BEKSAÇ MERAL,Spicka I,,Leleu X,,Schjesvold F,,Moreau P,,Dimopoulos MA,Huang JSY,Minarik J,,Cavo M,,Prince HM,Mace S,,Corzo KP,Campana F,,LeGuennec S,,Dubin F,,Anderson KC
• Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients? - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients? - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients? - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients? - İLHAN OSMAN,CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Maintenance Therapy with the Oral Proteasome Inhibitor Ixazomib Significantly Prolongs Progression-Free Survival Post-Autologous Stem Cell Transplantation Vs Placebo in Patients with Newly Diagnosed Multiple Myeloma: Phase 3 TOURMALINE-MM3 Trial - Kaiser M,,Dimopoulos MA,Gay F,,Schjesvold FH,BEKSAÇ MERAL,Hajek R,,Weisel KC,Goldschmidt H,,Maisnar V,,Moreau P,,Min CK,Pluta A,,Chng WJ,Zweegman S,,Mateos MV,Spencer A,,Iida S,,Morgan GJ,Suryanarayan K,,Teng Z,,Skacel T,,Palumbo A,,Dash AB,Gupta N,,Labotka R,,Rajkumar SV
• The Effect Of Predıcted Indırectly Recognızable Hla Epıtopes Presented By Hla-Class Iı Molecules On 1 Antıgen/Alelle Mısmatched Unrelated Hsct: A Sıngle Center Experıence - DALVA KLARA,CENGİZ SEVAL GÜLDANE,OZ dilek,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,Alnıaçık EZGİ,ALTAN HİLAL,ALNIAÇIK RIDVAN,SERTEL SUAT,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• The Effect Of Predıcted Indırectly Recognızable Hla Epıtopes Presented By Hla-Class Iı Molecules On 1 Antıgen/Alelle Mısmatched Unrelated Hsct: A Sıngle Center Experıence - DALVA KLARA,CENGİZ SEVAL GÜLDANE,OZ dilek,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,Alnıaçık EZGİ,ALTAN HİLAL,ALNIAÇIK RIDVAN,SERTEL SUAT,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Hematolojik Maligniteli Hastalarda Haploidentik Kök Hücre Nakillerinde Mezenkimal Kök Hücre Uygulaması - ARSLAN ÖNDER,ELÇİN AYŞE ESER,ATİLLA ERDEN,ŞEKER ŞÜKRAN,BAYDIN PINAR,GÜNDÜZ MEHMET,ÖZEN MEHMET,BAYRAKTAR ULAŞ DARDA,İLHAN OSMAN,BEKSAÇ MERAL,ELÇİN YAŞAR MURAT,GÜRMAN GÜNHAN
• İmmun Trombositopeni (İTP) hastalarında ABO kan gruplarının birinci basamak tedavi yanıtına etkisi - AKKUŞ ERMAN,FİDAN ÇİĞDEM,KUŞTAŞ ALİ AYTUĞ,NARLI ÖZDEMİR ZEHRA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN,YÜKSEL MELTEM
• Clinical experiences from around the world - BEKSAÇ MERAL
• A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF DARATUMUMABMONOTHERAPY FOR PATIENTS (PTS) WITH INTERMEDIATE OR HIGH-RISK SMOLDERINGMULTIPLE MYELOMA (SMM): CENTAURUS - CAVO M,,Hofmeister CC,Chari A,,Cohen YC,Spencer A,,Voorhees P,,Estell J,,Venner C,,Sandhu I,,Jenner M,,C, Williams,van de Donk N,,BEKSAÇ MERAL,Kuppens S,,Bandekar R,,Neff T,,Heuck C,,Qi M,,Goldschmidt H,,Landgren CO
• Addressing Unmet Medical Needs in Maintenance Treatment for Newly Diagnosed Multiple Myeloma (NDMM) - Lonial S,,Chng WJ,BEKSAÇ MERAL,Hajek R,,Weisel K,,Mateos MV,Spencer A,,Iida S,,D, de Farias,Labotka R,,Skacel T,,Palumbo A,,Kumar S,,Dimopoulos M,
• Consolıdatıon Followed By Maıntenance Vs Maıntenance Alone In Newly Dıagnosed, Transplant Elıgıble Multıple Myeloma: A Randomızed Phase 3 Study Of The European Myeloma Network (Emn02/Ho95 Mm Trıal) - Sonneveld P,,BEKSAÇ MERAL,vanderHolt M,,Dimopoulos MA,Carella A,,Ludwig H,,Driessen C,,Wester R,,Hajek R,,Cornelisse P,,Troia R,,Dozza L,,Gay F,,Cafro A,,De Rosa L,,Fiontoni G,,Mellqvis UH,Johnsen HE,Zweegman S,,Wu KL,Parreira J,,Schjesvold FH,DRozario J,,Palumbo AP,Boccadoro M,,Cavo M,
• Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE) - Cavo M,,Lida S,,Blade J,,Mateos MV,Lee JJ,Garg M,,Hungria V,,BEKSAÇ MERAL,Spicka I,,Knop S,,Pour L,,Campbell P,,Jakubowiak AK,Wang J,,Wroblewski S,,Kobos R,,Qi M,,Miguel JS
• Addressıng Unmet Medıcal Needs In Maıntenance Treatment For Newly Dıagnosed Multıple Myeloma (NDMM): Current Treatment Landscape And Emergıng Therapeutıc Optıons - Chng WJ,BEKSAÇ MERAL,Hajek R,,Weisel K,,Mateos MV,Spencer A,,Lida S,,Farias D,,Labotka D,,Skacel T,,Palumbo A,,Lonial S,,Kumar S,,Dimopoulos MA
• State of the art myeloma treatment in Turkey and southeastern European countries on the Balkan peninsula - BEKSAÇ MERAL
• IMiDs and proteasome inhibitors - BEKSAÇ MERAL
• Newly Diagnosed Patients With Multiple Myeloma Multiple - BEKSAÇ MERAL
• Optimal strategy for RRMM treatment - BEKSAÇ MERAL
• Ölçülebilir kalıntı hastalık ve klinik önemi - BEKSAÇ MERAL
• Optımısmm: Phase 3 Study Of Pomalıdomıde, Bortezomıb, And Low Dose Of Dexamentasone Vs. Bortezomıb And Low Dose Of Dexamethasone In Patıents Exposed To Lenalıdomıde After Fırst Collectıon Of Multıple Myeloma - Oriol A,,Richardson P,,BEKSAÇ MERAL,Liberati AM,Galli M,,Schjesvold F,,Lindsay J,,Weisel K,,White D,,Facon T,,Sunami K,,OGorman P,,Sonneveld P,,Robak P,,Semochkin S,,Schey S,,Yu X,,Doerr T,,Bensmaine A,,Biyukov T,,Caia A,,Zaki M,,Anderson K,,Dimopoulos M,,Miguel JS
• Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial - Dimopoulos MA,Gay F,,Schjesvold FH,BEKSAÇ MERAL,Hajek R,,Weisel K,,Goldschmidt H,,Maisnar V,,Moreau P,,CK Min,Pluta A,,Chng WJ,Kaiser M,,Zweegman S,,Mateos MV,Spencer A,,Iida S,,Morgan G,,Teng Z,,Suryanarayan K,,Skacel T,,Dash AB,Labotka R,,Rajkumar SV
• Ölçülebilir kalıntı hastalık ve klinik önemi - BEKSAÇ MERAL
• Ölçülebilir kalıntı hastalık ve klinik önemi - BEKSAÇ MERAL
• State of the art myeloma treatment in Turkey and southeastern European countries on the Balkan peninsula - BEKSAÇ MERAL
• State of the art myeloma treatment in Turkey and southeastern European countries on the Balkan peninsula - BEKSAÇ MERAL
• Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial - Richardson PG,Rocafiguera AO,BEKSAÇ MERAL,Liberati AM,Galli M,,Schjesvold F,,Lindsay J,,Weisel K,,White D,,Facon T,,Miguel JS,Sunami K,,OGorman P,,Sonneveld P,,Yu X,Doerr T,,Bensmaine A,,Zaki MH,Anderson KC,MA Dimopoulos
• Daratumumab Plus Bortezomıb-Melphalan-Prednısone (Vmp) In Elderly (≥75 Years Of Age)Patıents Wıth Newly Dıagnosed Multıple Myeloma Inelıgıble For Transplantatıon (Alcyone) - Miguel JS,Iida S,,Blade J,,Mateos MV,Lee JJ,Garg M,,Hungria V,,BEKSAÇ MERAL,Spicka I,,Knop S,,Pour L,,Campbell P,,Jakubowiak A,,Bauer MK,Wang J,,Wroblewski S,,Kobos R,,Qi M,,Cavo M,
• OPTIMISMM: PHASE 3 STUDY OF POMALIDOMIDE, BORTEZOMIB, AND LOW DOSE OF DEXAMENTASONE VS. BORTEZOMIB AND LOW DOSE OF DEXAMETHASONE IN PATIENTS EXPOSED TO LENALIDOMIDE AFTER FIRST COLLECTION OF MULTIPLE MYELOMA - Richardson P,,Rocafiguera AO,BEKSAÇ MERAL,Liberati M,,Galli M,,Schjesvold F,,Lindsay J,,Weisel K,,White D,,Facon T,,Miguel JS,Sunami K,,OGorman P,,Sonneveld P,,Robak P,,Semochkin S,,Schey S,,Yu X,,Doerr T,,Bensmaine A,,Biyukov T,,Peluso T,,Zaki M,,Anderson K,,Dimopoulos M,
• Fit Elderly Patients with aggressive lymphoma do not needdose reduction of conditioning regimen - İLHAN OSMAN,SEVAL GÜLDANE CENGİZ,USLU ATİLLA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience - GÜRMAN GÜNHAN,SEVAL GÜLDANE CENGİZ,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,BEKSAÇ MERAL,AKAN HAMDİ
• Retrospective Analysis of 149 Unselected Patients with Mantle Cell Lymphoma Confirms Prognostic Relevance of Mantle Cell Lymphoma International Prognostic Index: Single Center Experience - SEVAL GÜLDANE CENGİZ,ULAŞ BELİZ BAHAR,Taşçı Onur,Özel Fulya,Bulat Buğu,KUZU IŞINSU,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ÖZCAN MUHİT,BEKSAÇ MERAL,İLHAN OSMAN,GÜRMAN GÜNHAN,ARSLAN ÖNDER
• ANTİ-CD38 MONOKLONAL ANTİKOR TEDAVİSİ ALANMULTİPLE MYELOM HASTALARINDA ERİTROSİTTRANSFÜZYONUNA YAKLAŞIM - USLU ATİLLA,SEVAL GÜLDANE CENGİZ,NARLI ÖZDEMİR ZEHRA,ERSOY HAKAN,BEKSAÇ MERAL,TOPÇUOĞLU PERVİN
• Impact of Hepatitis B Core Antibody Seopositivity on theLiver Function Tests after Autologous Hematopoietic StemCell Transplantation For Multiple Myeloma - SEVAL GÜLDANE CENGİZ,SERTESEN ELİF,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,TOPRAK SELAMİ KOÇAK
• Kır2ds4’ün Miyelom Plazma Hücrelerine Karşı Otolog Veya Kordon Kanı Doğal Öldürücü Hücre Aracılıklı Toksisitede Rolü - YURDAKUL MESUTOĞLU PINAR,AKIN HY,,BUNSUZ MS,TURASAN E,,MERTER MUSTAFA,ÖZTÜRK C,,DALVA KLARA,BEKSAÇ MERAL
• Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM) - Landgren O,,Cavo M,,Chari A,,Cohen YC,Spencer A,,Voorhees PM,,Estell J,,Sandhu I,,Jenner M,,Williams C,,van de Donk NWCJ,BEKSAÇ MERAL,Goldschmidt H,,Moreau P,,Kuppens S,,Bandekar R,,Neff T,,A, Cortoos,Clemens PL,Qi M,,Adams H,,Hofmeister CC,
• Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial - Bruinink DH,van Duin M,,BEKSAÇ MERAL,Driessen C,,Ludwig H,,Vermeulen M,,Kuiper R,,Vliet MH,van der Holt B,,Hajek R,,Johnsen HE,Dimopoulos MA,Palumbo A,,Cavo M,,Sonneveld P,
• A Cross Sectional Epidemiological and Survival Analysis of All Patients with Plasma Cell Disorders Recorded between 2011- 2017 in the Social Insurance System of Turkey - Dag M,,BEKSAÇ MERAL
• Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients - ATİLLA ERDEN,TOPÇUOĞLU PERVİN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,DEMİRER TANER,ÖZCAN MUHİT,BEKSAÇ MERAL,İLHAN OSMAN,AKAN HAMDİ,ARSLAN ÖNDER,GÜRMAN GÜNHAN,TOPRAK SELAMİ KOÇAK
• Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM) - Chng WJ,BEKSAÇ MERAL,Hajek R,,Weisel K,,Mateos MV,Spencer A,,Lida S,,Farias D,,Labotka R,,Skacel T,,Palumbo A,,Lonial S,,S, Kumar,Dimopoulos MA
• Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). - Lonial S,,Dimopoulos MA,Weisel K,,White D,,Moreau P,,Mateos MV,Miguel JS,Anderson KC,Shpilberg O,,Grosicki S,,Spicka I,,Croneck AW,Magen H,,Belch A,,Reece DE,BEKSAÇ MERAL,Shelat S,,Sy O,,Singhal AK,Richardson PG
• Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience - Cengiz Seval G,,BULAT B,,Ozel F,,Tasci O,,Kuzu I,,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ÖZCAN MUHİT,GÜRMAN GÜNHAN,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,ARSLAN ÖNDER
• Patıent Reported Outcomes (Pros) Of Multıple Myeloma (Mm) Patıents From The Panorama-1 Study Who Have Receıved At Least Two Prıor Regımens Includıng Bortezomıb And An Immunomodulatory Agent - Richardson PG,Hungria V,,Yoon SS,BEKSAÇ MERAL,Dimopoulos MA,Elghandour A,,Jedrzejczak WW,Nakorn TN,Siritanaratkul N,,Schlossman R,,Hou J,,Moreau P,,Lonial S,,Lee JH,Einsele H,,Binlich F,,Sopala M,,Roy A,,Panneerselvam A,,Miguel JS
• Real World Retrospectıve Analysıs Of Extramedullary Dısease From Balkan Myeloma Study Group And Barcelona Unıversıty: Clınıcal Features And Outcome - BEKSAÇ MERAL,Kanellias N,,Rosinol L,,CENGİZ GS,Ozet G,,Goranova V,,Coriu D,,Bila J,,Ozsan H,,Balic LI,Ivanaj A,,Kastritis E,,Blade J,,Dimopoulos MA
• Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM) - Weisel K,,Dimopoulos MA,Lonial S,,White D,,Moreau P,,Mateos MV,Miguel JS,Anderson K,,Shpilberg O,,Grosicki S,,Spicka I,,Croneck AW,Magen H,,Belch A,,Reece D,,BEKSAÇ MERAL,Shelat SG,Mekan S,,O, Sy,Singhal AK,Richardson PG
• Impact Of Mesenchymal Stromal Cells On In Vıtro Growth Of Fresh Human Myeloma Plasma Cells And On Autologous/Cord Blood Nk Cell Medıated Cytotoxıcıty - YURDAKUL MESUTOĞLU PINAR,AKIN HY,AYDIN G,,SENGUN MB,TURASAN E,,DALVA KLARA,BEKSAÇ MERAL
• Impact Of Mesenchymal Stromal Cells On In Vıtro Growth Of Fresh Human Myeloma Plasma Cells And On Autologous/Cord Blood Nk Cell Medıated Cytotoxıcıty - YURDAKUL MESUTOĞLU PINAR,AKIN HY,AYDIN G,,SENGUN MB,TURASAN E,,DALVA KLARA,BEKSAÇ MERAL
• Real-World Data in Relapsed Refractory Myeloma Patients Treated with Pomalidomide, a Multicenter Turkish Experience - ÖZSAN GÜNER HAYRİ,SEVİNDİK ÖMÜR GÖKMEN,SEVİL SADRİ,HACIOĞLU SİBEL KABUKCU,KAYA SÜREYYA YİĞİT,GEDUK AYFER,URAL ALİ UĞUR,TUĞLULAR TÜLİN FIRAT,ÖZKOCAMAN VİLDAN,DEMİR AHMET MUZAFFER,AYDIN YILDIZ,ÇAĞLAYAN GÜLSÜM AKGÜN,AYDOĞDU İSMET,PEHLİVAN MUSTAFA,YARADILMIŞ İBRAHİM MUAZ,KARAKUŞ VOLKAN,YILMAZ MEHMET,BEKSAÇ MERAL
• Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma - ATİLLA ERDEN,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,AKAN HAMDİ,ARSLAN ÖNDER,DEMİRER TANER,BEKSAÇ MERAL,İLHAN OSMAN,ÖZCAN MUHİT,GÜRMAN GÜNHAN
• Phase 3 ELOQUENT-2 study: extended 4-y follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM) - Lonial Sagar,Singhal Anil,Moreau Philippe,Shpilberg Ofer,Reece Donna,Mateos Maria,Grosicki Sebastian,Belch Andrew,White Darrell,Sy Oumar,San Miguel Jesus,Magen nativ Hila,Walter Croneck Adam,BEKSAÇ MERAL,Dimopoulos Meletios,Spicka Ivan,Weisel Katja,Richardson Paul,Anderson Kenneth,Mekan Sabeen
• ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI GELİŞENKARACİĞER SİNÜZOİDAL TIKANIKLIK SENDROM İNSİDANSIVE KLİNİK BULGULAR - GÜNDÜZ MEHMET,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN,TOPÇUOĞLU PERVİN
• Clinical Autologous Transplantation - BEKSAÇ MERAL
• Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study - Hofmeister CC,Chari A,Cohen Y,Voorhee PM,Estel J,Venner CP,Sandhu I,Jenner MW,Williams C,Cavo M,Donk NV,BEKSAÇ MERAL,Kuppens S,Bandekar R,Neff T,Heuck C,Qi M,Goldschmidt H,Landgren O
• Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study - Cavo M,Hjek R,Pantani L,BEKSAÇ MERAL,Oliva S,Dozza L,Johnsen HE,Petrucci MT,Mellqvist UH,Conticello C,Driessen C,Marzocchi G,Dimopoulos MA,Zweegman S,Wu KL,Gamberi B,Crippa C,Holt BV,Offidani M,Wester R,Vincelli ID,Troia R,Cornelisse P,Boccadoro M,Sonneveld P
• REAL WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH POMALIDOMIDE, A MULTICENTER TURKISH EXPERİENCE - ÖZSAN GÜNER HAYRİ,SEVİNDİK ÖMÜR GÖKMEN,sevil sadri,HACIOĞLU SİBEL,KAYA SÜREYYA,GEDUK AYFER,URAL ALİ UĞUR,TUĞLULAR AYŞE TÜLİN,ÖZKOCAMAN VİLDAN,DEMİR AHMET MUZAFFER,AYDIN YILDIZ,AKGÜN ÇAĞLIYAN GÜLSÜM,AYDOĞDU İSMET,PEHLİVAN MUSTAFA,YARADILMIŞ İBRAHİM MUAZ,KARAKUŞ VOLKAN,YILMAZ MEHMET,BEKSAÇ MERAL
• Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma - İLHAN OSMAN,ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA - Dimopoulos MA,Lonial S,White D,Moreau P,Mateos MV,San Miguel J,Anderson KC,Shpilberg O,Grosicki S,Spicka I,A WalterCroneck,Magen H,Belch A,Reece DE,BEKSAÇ MERAL,Mekan S,Sy O,Singhal AK,Richardson PG,Weisel K
• HLA C1/C1 Homozygosity Decreases Relapse Rate After Allogeneic Hematopoietic Stem Cell Transplantation (Allo- HSCT) in Acute Myeloid Leukemia (AML) Patients - ATİLLA ERDEN,DALVA KLARA,ATACA ATİLLA PINAR,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,Gulbas Zafer,ARAT MUTLU,Yesilipek Akif,Oguz Fatma Sayran,BEKSAÇ MERAL
• Phase 3 ELOQUENT-2 study: extended 4-year follow-up of Elotuzumab plus lenalidomide/ dexamethasone vs lenalidomide/ dexamethasone in relapsed/ refractory multiple myeloma - Weisel K,Dimopoulos MA,Lonial S,White D,Moreau P,Mateos MV,San Miguel J,Anderson KC,Shpilberg O,Grosicki S,Spicka I,WalterCroneck A,Magen H,Belch A,Reece DE,BEKSAÇ MERAL,Mekan S,Sy O,Singhal AK,Richardson PG
• Bortezomib-Based Therapy Overcomes the Adverse Impact of Renal Impairment in Transplant Eligible Patients : An Analysis of the Prospective Randomized EMN02/HO95 Study - Dimopoulos MA,Kastritis E,Hajek R,Dozza L,BEKSAÇ MERAL,Larocca A,Johnsen HE,Mellqvist UH,Waage A,Zweegman S,Ludwig H,Pantani L,Spencer A,Pascarella A,Martello M,Carvalho S,Steingrimsdottir H,Cellini C,P Cornelisse,Troia R,Tosi P,Holt BVD,Boccadoro M,Sonneveld P,Cavo M
• REAL-WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH POMALIDOMIDE , A MULTI CENTER TURKISH EZXPERIENCE - ÖZSAN GÜNER HAYRİ,SEVİNDİK ÖMÜR GÖKMEN,SADRİ SEVİL,HACIOĞLU SİBEL,KAYA SÜREYYA,GEDUK AYFER,URAL ALİ UĞUR,TUĞLULAR AYŞE TÜLİN,ÖZKOCAMAN VİLDAN,DEMİR AHMET MUZAFFER,AYDIN YILDIZ,AKGÜN ÇAĞLIYAN GÜLSÜM,AYDOĞDU İSMET,PEHLİVAN MUSTAFA,YARADILMIŞ İBRAHİM MUAZ,KARAKUŞ VOLKAN,YILMAZ MEHMET,BEKSAÇ MERAL
• Management and Outcome of Central Nerve System(CNS) Involvement in Acute Lymphoblastic Leukemia - ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,AKAN HAMDİ,BEKSAÇ MERAL,İLHAN OSMAN,GÜRMAN GÜNHAN
• Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients - ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL
• AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: SINGLE CENTER EXPERIENCE - TOPRAK SELAMİ KOÇAK,ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,DEMİRER TANER,ÖZCAN MUHİT,ARAT MUTLU,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,konuk nahide,uysal akın,GÜRMAN GÜNHAN
• Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia. - GÜRMAN GÜNHAN,gülöksüz gözde aydemir,ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ÖZCAN MUHİT,ARSLAN ÖNDER,DEMİRER TANER,İLHAN OSMAN,BEKSAÇ MERAL
• A single center experience with two decades of follow-up on patients with hairy cell leukemia. - İLHAN OSMAN,ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,DEMİRER TANER,ARSLAN ÖNDER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• ALLOEGENEİC HEMATOPOİETİC STEM CELL TRANSPLANTATİON İN ADVANCED AGE ADULTS:İS İT POSSİBLE TO TRANSPLANT SAFELY? - ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,AKAN HAMDİ,GÜRMAN GÜNHAN,ÖZCAN MUHİT,BEKSAÇ MERAL,ARSLAN ÖNDER,TOPÇUOĞLU PERVİN,İLHAN OSMAN
• peripheral blood stem cell mobilization and collection from elderly patients with multiple myeloma:A single center experience - seval güldane,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,AKAN HAMDİ,BEKSAÇ MERAL,İLHAN OSMAN
• Kronik Myeloproliferatif Neoplazilerde Kalretikulin (CALR) mutasyonu - Öztekin Şüra,ÖCAL ELİF,Boyacıgil Şenay,ÖZCAN MUHİT,BEKSAÇ MERAL,ARSLAN ÖNDER,TOPÇUOĞLU PERVİN,koçak toprak selami,GÜRMAN GÜNHAN,KUZU IŞINSU
• Peripheral blood stem cell mobilization and collectionfrom elderly patients (≥65 years) with multiple myeloma: Asingle center experience - seval güldane cengiz,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,AKAN HAMDİ,BEKSAÇ MERAL,İLHAN OSMAN
• HLA C1/C1 homozygosity decreases relapse rate afterallogeneic hematopoietic stem cell transplantation(Allo-HSCT) in acute myeloid leukemia (AML) patients - ATİLLA ERDEN,DALVA KLARA,ATACA ATİLLA PINAR,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,gülbaş zafer,ARAT MUTLU,YEŞİLİPEK MEHMET AKİF,savran fatma oğuz,BEKSAÇ MERAL
• Allogeneic hematopoietic stem cell transplantation(allo-HSCT) in advanced age adults: is it possible totransplant safely? - ATİLLA ERDEN,baŞ o,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,AKAN HAMDİ,GÜRMAN GÜNHAN,ÖZCAN MUHİT,BEKSAÇ MERAL,ARSLAN ÖNDER,TOPÇUOĞLU PERVİN,İLHAN OSMAN
• HLA C1/C1 homozygosity decreases relapse rate after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in acute myeloid leukemia (AML) patients - ATİLLA ERDEN,DALVA KLARA,ATACA ATİLLA PINAR,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,Gülbaş Zafer,ARAT MUTLU,YEŞİLİPEK MEHMET AKİF,Savran Fatma,BEKSAÇ MERAL
• Management and Outcome of Central Nervous System (CNS) Involvement in Acute Lymphoblastic Leukemia (ALL) - ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,AKAN HAMDİ,BEKSAÇ MERAL,İLHAN OSMAN,GÜRMAN GÜNHAN,ÖZCAN MUHİT
• Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients - GÜRMAN GÜNHAN,ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL
• Age Is Not Important for Autologous Peripheral Hematopoietic Stem Cell Transplantation in Multiple Myeloma - İLHAN OSMAN,Güldane Cengiz,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,Özel Fulya,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma - ATİLLA ERDEN,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,AKAN HAMDİ,ARSLAN ÖNDER,DEMİRER TANER,BEKSAÇ MERAL,İLHAN OSMAN,GÜRMAN GÜNHAN
• Gebelikte Kök Hücre Faktör (SCF) ve Granülosit Koloni Stimüle Edici Faktör (G-CSF) Düzeyleri ve in vitro Etkileri - AKIN HY,YURDAKUL PINAR,KATLAN DORUK CEVDİ,ÖRGÜL GÖKÇEN,BEKSAÇ MEHMET SİNAN,BEKSAÇ MERAL
• Maternal ve Fetal Serum Örneklerinde Hematopoietik Sitokinler Olan Kök Hücre Faktör (Stem Cell Factor=SCF) ve Granülosit Koloni Stimule Edici Faktör (G-CSF) Düzeylerinin ve in vitro Etkilerinin Karşılaştırılmalı Analizi. - Akın HY,KATLAN DORUK CEVDİ,ÖRGÜL G,BEKSAÇ MEHMET SİNAN,BEKSAÇ MERAL
• Multiple Myeloma ‘da Risk Temelli Tedaviler - BEKSAÇ MERAL
• Türkiye’den Çok Merkezli Erken Erişim Program Sonuçları: Daha Önce Yoğun Tedavi Almış Relaps/Refrakter Multipl Miyelom Hastalarında Daratumumabın Etkililik ve Güvenliliği - BEKSAÇ MERAL,GOKER H,TURGUT M,AYDIN Y,BESİSİK SK,Cagirgan S,Tuglular T,Vural F,Yagci M,ALACACIOĞLU İNCİ,AYTAN PELİN,Göksoy HS,Gülbaş Z,Güneş AK,Gürkan E,Hacıoğlu SK,Kartı SS,Kaynar L,ÖZDOĞU HAKAN,PAYDAŞ SEMRA,SOLMAZ SONER,Sönmez M,Tekgündüz E,Yıldırım R,İLHAN OSMAN
• Maternal ve Fetal Serum Örneklerinde Hematopoietik Sitokinler Olan Kök Hücre Faktör (Stem Cell Factor=SCF) ve Granülosit Koloni Stimule Edici Faktör (G-CSF) Düzeylerinin ve in vitro Etkilerinin Karşılaştırılmalı Analizi - Akın HY,YURDAKUL PINAR,KATLAN DORUK CEVDİ,Örgül G,BEKSAÇ MEHMET SİNAN,BEKSAÇ MERAL
• Propensity Score Matching Analysis to Evaluate the Comparative Effectiveness of Daratumumab versus Real-World Standard of Care Therapies for Patients with Heavily Pretreated and Refractory Multiple Myeloma, PSM Dara vs IMF Cohort Manuscript - BEKSAÇ MERAL
• Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. - Ludwig H,Delforge M,Facon T,Einsele H,Gay F,Moreau P,Avet Loiseau H,Boccadoro M,Hajek R,Mohty M,Cavo M,Dimopoulos MA,San Miguel CF,Terpos E,Zweegman S,Garderet L,Mateos MV,Cook G,Leleu X,Goldschmidt H,Jackson G,Kaiser M,Weisel K,van de Donk NWDJ,Waage A,BEKSAÇ MERAL,Mellqvist UH,Engelhardt M,Caers J,Driessen C,Sonneveld P
• NEXT GENERATION SEQUENCING METHODOLOGY FOR DETERMINING CYTOGENETIC RISK STATUS IN THE DARATUMUMAB PHASE 3 CASTOR AND POLLUX STUDIES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA - Chiu C,Soong D,I Spicka,BEKSAÇ MERAL,Schaffer M,Schecter T,Bahlis NJ,Dimopoulos MA
• Autologous Stem Cell Trnasplantation for Mantle Cell Lymphoma: A Single Center Exprience - TOPRAK SELAMİ KOÇAK,ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,DEMİRER TANER,ARSLAN ÖNDER,ÖZCAN MUHİT,ARAT MUTLU,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,NAHİDE KONUK,UYSAL AKIN,GÜRMAN GÜNHAN
• Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantationd for acute myeloid leukemia - GÜRMAN GÜNHAN,AYDEMİR GULOKSUZ GÖZDE,ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ÖZCAN MUHİT,ARSLAN ÖNDER,DEMİRER TANER,AKAN HAMDİ,İLHAN OSMAN,BEKSAÇ MERAL
• Allojeneik stem cell transplantation results in our myelodysplastic sydrome (MDS) patientes - GÜRMAN GÜNHAN,ATACA ATİLLA PINAR,AYDIN TOLGA,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ÖZCAN MUHİT,DEMİRER TANER,BEKSAÇ MERAL,İLHAN OSMAN,AKAN HAMDİ,KONUK NAHİDE,ARSLAN ÖNDER
• A single center experience With two decades of follow-up on patients With hairy cell leukemia - İLHAN OSMAN,ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,DEMİRER TANER,ARSLAN ÖNDER,ÖZCAN MUHİT,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Peripheral Blood Stem Cell Mobilization and collection from elderly patients 65 years with multipl myeloma: A , single center exprience - CENGİZ SEVAL GÜLDANE,TOPRAK SELAMİ KOÇAK,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,İLHAN OSMAN,ÖZCAN MUHİT,GÜRMAN GÜNHAN,BEKSAÇ MERAL,AKAN HAMDİ
• Allegeneic Hematopoetic Stem Cell Trnasplantation (Allo-HSCT) in advanced age adults:Is it possible to transplant safely? - ATİLLA ERDEN,BAŞ ÖZGE,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,AKAN HAMDİ,GÜRMAN GÜNHAN,ÖZCAN MUHİT,TOPÇUOĞLU PERVİN,BEKSAÇ MERAL,ARSLAN ÖNDER,İLHAN OSMAN
• Acute GVHD and unreated/haploidentical Trnasplants incrreses the incidence of hemorrhagic cystitis in Allo- HSCT Recipients - TOPÇUOĞLU PERVİN,ATİLLA ERDEN,ATACA ATİLLA PINAR,USLU ATİLLA,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,DEMİRER TANER,ARSLAN ÖNDER,ÖZCAN MUHİT,İLHAN OSMAN,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Herpes SimplexVirus infection in patients after allogeneic hematopoetic stem cell transplantation - ATİLLA ERDEN,ÖZEL FULYA,YILMAZ VOLKAN,ATACA ATİLLA PINAR,ATEŞAĞAOĞLU BERNA,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,AKAN HAMDİ,DEMİRER TANER,ARSLAN ÖNDER,ÖZCAN MUHİT,İLHAN OSMAN,BEKSAÇ MERAL,GÜRMAN GÜNHAN
• Hematolojik Maligniteli Hastalarda Haploidentik Kök Hücre Nakillerinde Mezenkimal Kök Hücre Uygulaması. - ARSLAN ÖNDER,ELÇİN AYŞE ESER,ATİLLA ERDEN,ŞEKER ŞÜKRAN,BAYDIN PINAR,GÜNDÜZ MEHMET,ÖZEN MEHMET,BAYRAKTAR ULAŞ DARDA,İLHAN OSMAN,BEKSAÇ MERAL,ELÇİN YAŞAR MURAT,GÜRMAN GÜNHAN
• Positive Impact of Chronic Graft Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients - GÜRMAN GÜNHAN,ATACA PINAR,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,DEMİRER TANER,AKAN HAMDİ,ARSLAN ÖNDER,TOPÇUOĞLU PERVİN,BEKSAÇ MERAL
• Treatment of multiple myeloma (including autologous SCT) - BEKSAÇ MERAL,Gooneratne L,Pullaperuma R
• Treatment of multiple myeloma (including autologous SCT) - BEKSAÇ MERAL,Gooneratne L,Pullaperuma R
• Phase 3 ELOQUENT-2 study: extended 4-y follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM) - Lonial Sagar,Singhal Anil,Moreau Philippe,Shpilberg Ofer,Reece Donna,Mateos Maria,Grosicki Sebastian,Belch Andrew,White Darrell,Sy Oumar,San Miguel Jesus,Magen nativ Hila,Walter Croneck Adam,BEKSAÇ MERAL,Dimopoulos Meletios,Spicka Ivan,Weisel Katja,Richardson Paul,Anderson Kenneth,Mekan Sabeen
• HLA C1/C2 Homozygosity Decreases Relapse Rate After Allogeneic Hematopoietic Stem Cell Transplantation (Allo- HSCT) in Acute Myeloid Leukemia (AML) Patients - ATİLLA ERDEN,DALVA KLARA,ATACA ATİLLA PINAR,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,Gulbas Zafer,ARAT MUTLU,Yesilipek Akif,Oguz Fatma Sayran,BEKSAÇ MERAL
• Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma - Richardson PG,Hungria VTM,Yoon SS,BEKSAÇ MERAL,Dimopoulos MA,Elghandour A,Jedrzejczak WW,Guenther A,Nakorn TN,Siritanaratkul N,Schlossman RL,Hou J,Moreau P,Lonial S,Lee JH,Einsele H,Salwender H,Sopala M,Panneerselvam A,Redhu S,Corrado C,Binlich F,San Miguel JF
• Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients? - İLHAN OSMAN,ATACA ATİLLA PINAR,ATİLLA ERDEN,TOPRAK SELAMİ KOÇAK,Kaygusuz G,Kuzu I,CİVRİZ BOZDAĞ SİNEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,BEKSAÇ MERAL,DEMİRER TANER,AKAN HAMDİ,Konuk N,GÜRMAN GÜNHAN
• Do FMS-like Tyrosine Kinase 3 and Nucleophospmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ? - Gunduz M,ATACA ATİLLA PINAR,Ozen M,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,Ozcan M,DEMİRER TANER,BEKSAÇ MERAL,AKAN HAMDİ,GÜRMAN GÜNHAN,İLHAN OSMAN,Konuk N,ARSLAN ÖNDER
• Impact of PET-CT Response on Survival Parameters Following Autologous Stem Cell Transplantation Among Patients with Multiple Myeloma: Comparison of Two Cut-Off Values - BEKSAÇ MERAL,Gunduz M,Ozen M,Ozturk SMB,Kucuk O,Ozkan E
• Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt's Lymphoma: A Single Center Experience - ATİLLA ERDEN,Sahin U,ATACA ATİLLA PINAR,Uslu A,Kircali E,Atesagaoglu B,Pekcan G,MERTER MUSTAFA,Gunduz M,Ozen M,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,DEMİRER TANER,AKAN HAMDİ,GÜRMAN GÜNHAN,BEKSAÇ MERAL,İLHAN OSMAN,Konuk N,Ozcan M
• Age, Cytopenia at Diagnosis and History of Hypertension are associated with Stem Cell Mobilization Failures Among Patients with Multiple Myeloma - TOPRAK SELAMİ KOÇAK,Ozdogu H,ATİLLA ERDEN,TOPÇUOĞLU PERVİN,Uslu A,Kasar M,GÜRMAN GÜNHAN,İLHAN OSMAN,BEKSAÇ MERAL
• Generic (Bioequivalent) Melphalan Has Similar Efficacy and Toxicity but Lower Cost in the Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation - TOPÇUOĞLU PERVİN,Gultay D,Ozturk N,Kilic O,Okay M,Karadag YE,Cinar H,ATACA ATİLLA PINAR,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Konuk N,GÜRMAN GÜNHAN
• The relapse in acute leukemia after the allogeneic hematopoetic stem cell transplantation: No approaches have been superior yet - TOPÇUOĞLU PERVİN,Gunduz M,Ozen M,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Konuk N,Uysal A,GÜRMAN GÜNHAN
• Impact of Pre-transplant Serum Ferritin on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia - Sahin U,Erdal H,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Konuk N,GÜRMAN GÜNHAN
• Prognosis of Acute Leukemia Patients with Active Disease Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) - Sahin U,MERTER MUSTAFA,Atesagaoglu B,Erdai H,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Konuk N,GÜRMAN GÜNHAN
• Upper and lower respiratory tract infections by respiratory viruses in adult recipients of allogeneic hematopoeitic stem cell transplantation (Allo-HSCT): Single center - Sahin U,ATİLLA ERDEN,ATACA ATİLLA PINAR,Dolapci I,Tekeli A,Uslu A,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Konuk N,GÜRMAN GÜNHAN
• Erythrocytosis following allogeneic hematopoietic stem cell transplantation in six cases - Pekcan G,ATİLLA ERDEN,ATACA ATİLLA PINAR,TOPÇUOĞLU PERVİN,Uslu A,CİVRİZ BOZDAĞ SİNEM,Yuksel MK,ARSLAN ÖNDER,Ozcan M,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,GÜRMAN GÜNHAN,TOPRAK SELAMİ KOÇAK
• Different Doses of Anti-Thymocyte Globulin (ATG) in the Conditioning Regimen for Allogeneic Hematopoetic Stem Cell Transplantation - Pekcan G,Atesagaoglu B,MERTER MUSTAFA,TOPÇUOĞLU PERVİN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,Ates O,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Konuk N,GÜRMAN GÜNHAN
• Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Single Centre Experience - MERTER MUSTAFA,Sahin U,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,DALVA KLARA,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Konuk N,GÜRMAN GÜNHAN
• Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT): A Single Center Experience - MERTER MUSTAFA,Sahin U,Gunduz M,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Konuk N,GÜRMAN GÜNHAN
• HLA-A allele mismatch (7/8 or 9/10) is the second best option after 8/8 or 10/10 matched unrelated donors: An analysis on results from Turkish centers - BEKSAÇ MERAL,Oguz FS,TOPÇUOĞLU PERVİN,Karasu G,Arat M,Aksoylar S,Kansoy S,Besisik SK,Kupesiz A ,Hazar V,Altuntas F,Unail A,Gulbas Z,Sargin FD,İLHAN OSMAN,GÜRMAN GÜNHAN,Yesilipek A
• Are there any optimal cell doses for graft repopulation in the Bone Marrow-Derived Allogeneic Hematopoietic Stem Cell Transplantations? - ATACA ATİLLA PINAR,ATİLLA ERDEN,Altas U,Bay M,DALVA KLARA,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,AKAN HAMDİ,BEKSAÇ MERAL,Konuk N,Gurman G,İLHAN OSMAN
• Autologous Stem Cell Transplantation in Elderly Patients ( >=60 years) with Myeloma or Lymphoma: Single Center Experience - Gunduz M,ATİLLA ERDEN,ATACA ATİLLA PINAR,Pekcan G,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Konuk N,Gurman G
• Allogeneic Stem-Cell Transplantation for Hodgkin and non-Hodgkin Lymphoma: Single-center experience - ATİLLA ERDEN,Aydin T,MERTER MUSTAFA,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Konuk N,Gurman G
• Is there an optimum CD3+T cell dose for donor lymphocyte infusion? - CİVRİZ BOZDAĞ SİNEM,Kircali E,ATACA ATİLLA PINAR,ATİLLA ERDEN,Bay M,TOPRAK SELAMİ KOÇAK,Yuksel MK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Konuk N,Gurman G
• Is it possible to overcome the catastrophic complications of Hematopoietic Stem Cell Transplantation (HSCT) using Plasma Exchange (PE)?: A Single Center's Experience - Yuksel MK,Pekcan G,Ediboglu E,Bay M,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,BEKSAÇ MERAL,DEMİRER TANER,AKAN HAMDİ,Konuk N,Gurman G,İLHAN OSMAN
• HLA TYPING OF A MULTITRANSFUSED SCID PATIENT: WHAT NGS CAN TELL US? - DALVA KLARA,van de Pasch L,Topdagi D,Karagozlu S,Adema J,Aydincak H,Sertel S,Uguz E,Atilgan N,Rozemuller E,Ikinciogullari A,BEKSAÇ MERAL
• ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). - Lonial S,Dimopoulos MA,Palumbo A,White D,Grosicki S,Spicka I,WalterCroneck A,Moreau P,Mateos MV,MagenNativ H,Belch A,Reece DE,BEKSAÇ MERAL,Taniwaki M,Roellig C,Singhal AK,Katz J,Bleickardt EW,Poulart V,Richardson PG
• Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study. - Hungria VTM,San Miguel JF,Yoon SS,BEKSAÇ MERAL,Dimopoulos MA,Elghandour A,Jedrzejczak WW,Guenther A,Nakorn TN,Siritanaratkul N,Schlossman RL,Hou J,Moreau P,Lonial S,Lee JH,Einsele H,Sopala M,Bengoudifa BR,Corrado C,Richardson P
• Allogeneic stem cell transplantation results in our myelodysplastic syndrome (MDS) patients. - GÜRMAN GÜNHAN,ATACA ATİLLA PINAR,Aydin T,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,TOPÇUOĞLU PERVİN,Ozcan M,DEMİRER TANER,BEKSAÇ MERAL,İLHAN OSMAN,AKAN HAMDİ,Konuk N,ARSLAN ÖNDER
• SUBCUTANEOUS BORTEZOMIB IS AS EFFECTIVE AND LESS NEUROTOXIC THAN INTRAVENOUS BORTEZOMIB: ANKARA University EXPERIENCE - Atesagaglu B,TOPÇUOĞLU PERVİN,MERTER MUSTAFA,Sungurlu M,Sener O,BEKSAÇ MERAL
• POST-AUTHORIZATION SAFETY OF LENALIDOMIDE plus DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EARLY SAFETY REPORT OF TURKISH PASS STUDY - Tuglular ATF,Pehlivan M,Sari HI,Ayyildiz MO,Saydam G,Sonmez M,Besisik SK,Ozgur G,Gurkan E,Kaynar L,Ali R,Ozet G,Demirkan F,Ongoren S,Ozdogu H,Gunduz E,Tiftik EN,Salim O,Turgut M,Hacihanefioglu A,Ure UB,Ozdemir E,Altuntas F,Simsek D,Ulu N,BEKSAÇ MERAL
• COMPARISON OF RED BLOOD CELL AND PLASMA DEPLETION EFFICIENCIES OF TWO METHODS FROM CORD BLOOD: AUTOMATED SEPAX (BIOSAFE) AND MANUAL CELLEFFIC (KANEKA) - YURDAKUL PINAR,Gencer B,Akin HY,Sato N,BEKSAÇ MERAL,Fricke C
• FRONTLINE INDUCTION THERAPY FOR MULTIPLE MYELOMA (MM) IN REAL-WORLD CLINICAL PRACTICE: THIRD INTERIM ANALYSIS OF THE MULTINATIONAL, OBSERVATIONAL EMMOS STUDY (NCT01241396) - Mohty M,Terpos E,Mateos MV,Palumbo A,Legiec W,BEKSAÇ MERAL,Laane E,Bekadja MA,Nemet D,Peceliunas V,Cavo M,Moreau P,Masszi T,Cernelc P,de Oteyza JP,Salwender H,Abadi U,Dimopoulos M,Stankovic S,Salogub GN,Willenbacher W,Abildgaard N,Gunther K,Silva J,Lejniece S,Dyagil I,Potamianou A,Couturier C,Olie R,Feys C,ThoretBauchet F,Boccadoro M
• ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA - Dimopoulos M,Lonial S,Palumbo A,White D,Grosicki S,Spicka I,WalterCroneck A,Moreau P,Mateos MV,Magen H,Belch A,Reece D,BEKSAÇ MERAL,Oakervee H,Spencer A,Taniwaki M,Roellig C,Wu KL,Singhal A,San Miguel J,Matsumoto M,Katz J,Bleickardt E,Poulart V,Richardson P
• ANALYSIS OF OUTCOMES BY RESPONSE FOR PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PHASE 3 PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE - Moreau P,SanMiguel J,Hungria V,Yoon SS,BEKSAÇ MERAL,Dimopoulos M,Elghandour A,Jedrzejczak W,Guenther A,Nakorn T Na,Siritanaratkul N,Schlossman R,Hou J,S Lonial,Lee J H,Einsele H,Sopala M,Bengoudifa BR,Corrado C,Richardson P
• SUBGROUP ANALYSIS BY PRIOR TREATMENT AMONG PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE - Einsele H,Richardson P,Hungria V,Yoon SS,BEKSAÇ MERAL,Dimopoulos M,Elghandour A,Jedrzejczak W,Guenther A,Nakorn T Na,Siritanaratkul N,Schlossman R,Hou J,Moreau P,Lonial S,Lee J H,Sopala M,Bengoudifa BR,Corrado C,SanMiguel J
• ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone (ELd) vs Lenalidomide/Dexamethasone (Ld) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-3-Year Safety and Efficacy Follow-up - Dimopoulos M,Lonial S,White D,Moreau P,Palumbo A,San Miguel J,Shpilberg O,Anderson K,Grosicki S,Spicka I,Walter Croneck A,MagenNativ H,Mateos MV,Belch A,Reece D,BEKSAÇ MERAL,Bleickardt E,Poulart V,Katz J,Singhal AK,Richardson P
• Clinical Characteristics and Frequency of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation - Sahin U,Yuksel MK,MERTER MUSTAFA,Gunduz M,Ozdemir ZN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Gurman G
• Efficacy of High Dose Corticosteroid Premedication for the Prevention of Anti-thymocyte Globulin Related Side Effects - MERTER MUSTAFA,Sahin U,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,Yuksel MK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Gurman G,TOPRAK SELAMİ KOÇAK
• Effect of Cytomegalovirus Reactivation on Prognosis After Allogeneic Transplantation for Acute Leukemia with Active Disease Conditioned with a Sequential Regimen and Anti-Thymocyte Globulin - Gunduz M,Yuksel MK,Sahin U,MERTER MUSTAFA,Ozdemir ZN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,DEMİRER TANER,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL,Gurman G
• A CASE OF PROLONGED COAGULOPATHY CAUSED BY SUPERWARFARIN POISONING IN A WORKER - Narli Z,Sahin U,Kucukkaya RD,BEKSAÇ MERAL
• THERAPEUTIC THROMBOCYTAPHERESIS: HIGHER PLATELET COUNTS SHOULD MATTER - Narli Z,Sahin U,CİVRİZ BOZDAĞ SİNEM,Yuksel MK,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,Ozcan M,ARSLAN ÖNDER,DEMİRER TANER,BEKSAÇ MERAL,Gurman G,İLHAN OSMAN
• THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBULINURIA PATIENTS: SINGLE CENTER EXPERIENCE - MERTER MUSTAFA,Sahin U,Gunduz M,Ozdemir ZN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,Ozcan M,İLHAN OSMAN,BEKSAÇ MERAL,AKAN HAMDİ,Gurman G,Yuksel MK
• THERAPEUTIC PLASMA EXCHANGE FOR THROMBOTIC MICROANGIOPATHY - ATİLLA ERDEN,ATACA ATİLLA PINAR,Sahin U,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,DEMİRER TANER,Ozcan M,AKAN HAMDİ,BEKSAÇ MERAL,Gurman G,İLHAN OSMAN
• ARE AGE AND JAK2V617F MUTATION RELATED TO THROMBOSIS IN CHRONIC MYELOPROLIFERATIVE DISEASES? - ATACA ATİLLA PINAR,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Yuksel MK,TOPÇUOĞLU PERVİN,AKAN HAMDİ,ARSLAN ÖNDER,Ozcan M,BEKSAÇ MERAL,Gurman G,İLHAN OSMAN
• CD34 POSITIVE CELL COUNT DETECTED BY MULTI-COLOR FLOW CYTOMETRY (MFC) AFTER FIRST INDUCTION THERAPY IN ACUTE MYELOID LEUKEMIA (AML) EFFECTS ON SURVIVAL AND RELAPSE - ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,Yuksel MK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,BEKSAÇ MERAL,Ozcan M,İLHAN OSMAN,AKAN HAMDİ,DALVA KLARA,Gurman G,TOPRAK SELAMİ KOÇAK
• IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC SYNDROME (MDS) BY FLOW CYTOMETRY? - ATİLLA ERDEN,ATACA ATİLLA PINAR,Turedi O,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,AKAN HAMDİ,BEKSAÇ MERAL,ARSLAN ÖNDER,TOPÇUOĞLU PERVİN,Ozcan M,İLHAN OSMAN,Ruhi HI,Gurman G,DALVA KLARA
• OUR APPROACH TO HAIRY CELL LEUKEMIA HCL 31 YEARS OF EXPERIENCE - ATACA ATİLLA PINAR,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,AKAN HAMDİ,BEKSAÇ MERAL,İLHAN OSMAN,GÜRMAN GÜNHAN
• MANAGEMENT AND OUTCOME OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PRE AND POST TRANSPLANT - ATACA ATİLLA PINAR,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,TOPRAK SELAMİ KOÇAK,Topcuoglu P,ARSLAN ÖNDER,AKAN HAMDİ,BEKSAÇ MERAL,İLHAN OSMAN,GURMAN G,OZCAN M
• PHASE 3 RANDOMISED CONTROLLED STUDY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CASTOR - Palumbo A,ChananKhan A,Weisel K,Nooka AK,Masszi T,BEKSAÇ MERAL,Spicka I,Hungria V,Munder M,Mateos MV,Mark T,Qi X,Schecter J,Amin H,Qin X,Deraedt W,Ahmadi T,Spencer A ,Sonneveld P
• Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR - Weisel K,Palumbo A,ChananKhan A,Nooka A K,Spicka I,Masszi T,BEKSAÇ MERAL,Hungria V,Munder M,Mateos M V,Mark TM,Qi M,Schecter J,Amin H,Spencer A,Qin X,Deraedt W,Ahmadi T,Sonneveld P
• A benzamide derivative XT5 and imatinib combination induced apoptosis in Imatinib resistant K562 cell line - Ozkan T,Hekmatshoar Y,Bolelli T Ertan,BEKSAÇ MERAL,Yalcin E AKI,Yalcin I,Sunguroglu A
• PATIENT REPORTED OUTCOMES (PROS) OF MULTIPLE MYELOMA (MM) PATIENTS FROM THE PANORAMA-1 STUDY WHO HAVE RECEIVED AT LEAST TWO PRIOR REGIMENS INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT - Richardson PG,Hungria V,Yoon SS,BEKSAÇ MERAL,Dimopoulos MA,Elghandour A,Jedrzejczak WW,Jedrzejczak WW,Nakorn TN,Siritanaratkul N,Schlossman R,Hou J,Moreau P,Lonial S,Lee JH,Einsele H,Binlich F,Sopala M,Roy A,Panneerselvam A,San Miguel J
• BEING OVERWEIGHT/OBESE PRIOR TO ALLOJENEIK HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IS RELATED TO BETTER OVERALL SURVIVAL (OS) AND DECREASED NON-RELASE MORTALITY - ATİLLA ERDEN,ATACA ATİLLA PINAR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,AKAN HAMDİ,BEKSAÇ MERAL,ARSLAN ÖNDER,İLHAN OSMAN,ÖZCAN MUHİT,TOPRAK SELAMİ KOÇAK,GÜRMAN GÜNHAN
• Notch Ligandı Fibronektin Valproik Asit Nikotinamid ile Kordon Kanı Kök Hücrelerinin Ex Vivo Ekspansiyonu - Yurdakul Pinar,Gencer Emine Begum,Akin Hasan Yalim,DALVA KLARA,KATLAN DORUK CEVDİ,BEKSAÇ MEHMET SİNAN,BEKSAÇ MERAL
• Computer Aided Drug Design Studies on Human Protease Activated Receptor 1 as Anticancer Target - Aki Yalcin E,Hidayat A N,BEKSAÇ MERAL,Yalcin I
• IS 23 Molecular Modeling and ADMET Studies of some heterocylics on Human Protease Activated Receptor 1 asAnticancer Target - Aki Yalcin Esin,Hidayat Andry Nur,BEKSAÇ MERAL,Ertan Bolelli Tugba,Yalcin Ismail
• Hepatitis B HBV Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide Containing Regimens A Single Center Experience - ATACA PINAR,ATİLLA ERDEN,İDİLMAN RAMAZAN,BEKSAÇ MERAL
• Regrafting For Primary and Secondary Graft Failure - TOPÇUOĞLU PERVİN,ATİLLA ERDEN,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPRAK SELAMİ KOÇAK,ARSLAN ÖNDER,BEKSAÇ MERAL,ÖZCAN MUHİT,GÜRMAN GÜNHAN
• ELOQUENT 2 Extended safety and efficacy follow up of the phase 3 randomized open label study of elotuzumab in combination with lenalidomide dexamethasone in patients with relapsed refractory multiple myeloma - Dimopoulos M,Lonial S,White D,Moreau P,Palumbo A,J San Miguel,Shpilberg O,Anderson K,Grosicki S,Spicka I,Walter Croneck A,MagenNativ H,Mateos M V,Reece D,BEKSAÇ MERAL,Bleickardt E,Poulart V,Singhal A,Richardson P
• Intensification Therapy with Bortezomib Melphalan Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma An Intergroup Multicenter Phase III Study of the European Myeloma Network EMN02 HO95 MM Trial - Cavo Michele,BEKSAÇ MERAL,Dimopoulos Meletios,Pantani Lucia,Gay Francesca,Hajek Roman,Testoni Nicoletta,UlfHenrik Nicoletta,Patriarca Francesca,Montefusco Vittorio,Galli Monica,Johnsen Hans Erik,Ludwig Heinz,Zweegman Sonja,Wester Ruth,Wu Ka Lung,Driessen Christoph,Troia Rossella,Cornelisse Petra,van der Holt Bronno,Palumbo Antonio,Sonneveld Pieter
• EX VIVO Expansion of Human Cord Blood Comparison of Enhancers - Yurdakul Pinar,Gencer Emine Begum,Akin Hasan Yalim,DALVA KLARA,BEKSAÇ MERAL
• Ex Vivo Expansion of Human Umblical Cord Blood Hematopoietic Stem Cells HSC with Valproic Acid or Notch Ligand Fibronectin - Yurdakul Pinar,Gencer Emine Begum,Akin Hasan Yalim,DALVA KLARA,KATLAN DORUK CEVDİ,BEKSAÇ MERAL
• Comparative Proteomic Analysis of Bone Marrow Plasma Cells By Using Mass Spectrometry Based Bottom up Proteomic Strategies - DALVA KLARA,BEKSAÇ MERAL
• Outcomes after Initial Relapse of Multiple Myeloma An International Myeloma Working Group Study - BEKSAÇ MERAL
• Is Initial CD3 T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant - ATİLLA ERDEN,ATACA PINAR,TOPRAK SELAMİ KOÇAK,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,İLHAN OSMAN,BEKSAÇ MERAL
• Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation - ATİLLA ERDEN,ŞAHİN UĞUR,CİVRİZ BOZDAĞ SİNEM,YÜKSEL MELTEM,TOPÇUOĞLU PERVİN,ARSLAN ÖNDER,ÖZCAN MUHİT,DEMİRER TANER,GÜRMAN GÜNHAN,İLHAN OSMAN,AKAN HAMDİ,BEKSAÇ MERAL
• Eloquent 2 Update A Phase 3 Randomized Open Label Study of Elotuzumab in Combination with Lenalidomide Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma 3 Year Safety and Efficacy Follow up - BEKSAÇ MERAL
• The Effect of Pre Transplant Psychological Well Being on Hematological Reconstitution Following Autologous Stem Cell Transplantation in Multiple Myeloma Patients - TOPÇUOĞLU PERVİN,GÜRMAN GÜNHAN,BEKSAÇ MERAL
• Analysis Of Outcomes Based On Response İn Patients With Relapsed Or Relapsed And Refractory Multiple Myeloma Treated With Panobinostat Or Placebo İn Combination With Bortezomib And Dexamethasone İn The Panorama 1 Trial Updated Analysis Based On Prior Treatment - BEKSAÇ MERAL
• Final Analysis Of Overall Survival From The Phase 3 Panorama 1 Trial Of Panobinostat Plus Bortezomib And Dexamethasone Versus Placebo Plus Bortezomib And Dexamethasone İn Patients With Relapsed Or Relapsed And Refractory Multiple Myeloma - BEKSAÇ MERAL
• Analysis Of Final Data From The Multinational Non Interventional Observational Emmos Study NCT01241396 İn Patients Pts With Multiple Myeloma MM İn Real World Clinical Practice - BEKSAÇ MERAL
• Expression And İn Vitro Binding Of Protease Activated Receptor1 PAR1 With Novel Anti PAR1 Molecules Data On Fresh Myeloma Marrow Plasma Cells And Human Myeloma Cell Lines - ATACA PINAR,BEKSAÇ MERAL,DALVA KLARA
• Expression and in Vitro Binding of Protease Activated Receptor1 PAR1 with Novel Anti PAR1 Molecules Data on Fresh Myeloma Marrow Plasma Cells and Human Myeloma Cell Lines - BEKSAÇ MERAL,ATACA PINAR,ATESAGAOGLU BERNA,DALVA KLARA,HIDAYAT ANDRY NUR,YALCIN ISMAIL,YALCIN AKI ESIN,OZKAN TULIN,PAPANIKOLAOU XENOFON,Z USMANI SAAD,ERMING TIAN
• Hepatitis B HBV Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide Containing Regimens A Single Center Experience - ATACA PINAR,ERDEN ATILLA,KIRCALI EKIN,IDILMAN RAMAZAN,BEKSAÇ MERAL
• Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs A predefined subgroup analysis of PANORAMA 1 - MIGUEL SAN,JESUS F LOVERA,VANIA TM HUNGRIA,SUNG SOO YOON,BEKSAÇ MERAL
• Upgrade Of FDG PET Response Following Autologous Stem Cell Transplantation Is Associated With Better Progression Free Survival Among Patients With Multiple Myeloma - BEKSAÇ MERAL,TOPCUOGLU PERVIN,GUNDUZ MEHMET